

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	27	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China

NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:21:22 ON 30 MAR 2009

=> file caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'CAPLUS' ENTERED AT 14:21:32 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:21:32 ON 30 MAR 2009

=> glycolic and polyethylene glycol
GLYCOLIC IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s glycolic and polyethylene glycol
L1 1253 GLYCOLIC AND POLYETHYLENE GLYCOL

=> s l1 and polyvinyl
L2 203 L1 AND POLYVINYL

=> s l2 and skin
L3 29 L2 AND SKIN

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 29 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 ibib abs 1-29

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:138982 CAPLUS
DOCUMENT NUMBER: 150:199360
TITLE: Compositions and methods for dermally treating neuropathy with minoxidil
INVENTOR(S): Sanjay, Sharma; Zhang, Jie; Warner, Kevin S.

PATENT ASSIGNEE(S): Zars Pharma, Inc., USA
 SOURCE: PCT Int. Appl., 48pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009017767	A2	20090205	WO 2008-US9222	20080730
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080019927	A1	20080124	US 2007-888905	20070801
PRIORITY APPLN. INFO.:			US 2007-888905	A 20070801
			US 2004-577536P	P 20040607
			US 2005-146917	A2 20050606
			US 2005-750519P	P 20051214
			US 2005-750637P	P 20051214
			US 2006-640135	A2 20061214
			US 2006-640139	A2 20061214

AB The present invention is drawn to adhesive solidifying formulations containing minoxidil that can be used for treating neuropathies including diabetic neuropathy. The formulation can include an amount of minoxidil, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the minoxidil at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. Thus, a solidifying formulation for treating diabetic neuropathy and the associated neuropathic pain was prepared containing minoxidil 5, polyvinyl alc. 22.2, propylene glycol 22.2, ethanol 4.4, 5M HCl solution 1.8, and water 44.4%, resp. A solidified peel formulation was formed when the composition obtained was spread on a silicone-coated polyester release liner and the solidified peel was stretchable by 5% in one direction without cracking or splitting.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:583566 CAPLUS
 DOCUMENT NUMBER: 148:559911
 TITLE: Crystalline anti-human TNF- α antibodies
 INVENTOR(S): Borhani, David W.; Fraunhofer, Wolfgang; Krause, Hans-Juergen; Koenigsdorfer, Anette; Winter, Gerhard; Gottschalk, Stefan
 PATENT ASSIGNEE(S): Abbott Biotechnology Ltd., Bermuda
 SOURCE: PCT Int. Appl., 90pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008057240	A2	20080515	WO 2007-US22622	20071025
WO 2008057240	A9	20080828		
WO 2008057240	A3	20081106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-855104P P 20061027

AB The authors disclose batch crystallization methods for crystallizing an anti-human tumor

necrosis factor α (hTNF- α) antibody. These methods allow for the production of antibodies on an industrial scale.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:377734 CAPLUS

DOCUMENT NUMBER: 148:387269

TITLE: A novel bio-erodible collagen insert for ophthalmic applications and a process for the preparation thereof

INVENTOR(S): Hadassah, Janumala; Sehgal, Praveen Kumar

PATENT ASSIGNEE(S): Council of Scientific & Industrial Research, India

SOURCE: PCT Int. Appl., 27pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008035376	A2	20080327	WO 2007-IN374	20070830
WO 2008035376	A3	20081120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

IN 2006DE02064 A 20080404 IN 2006-DE2064 20060919

PRIORITY APPLN. INFO.: IN 2006-DE2064 A 20060919

AB The present invention provides a novel bio-erodible ophthalmic insert and a process for the preparation of the said bio-erodible insert using collagen treated with organic polar solvents, hydrophilic polymers and therapeutically active substances under controlled conditions. The resulting solution is air

dried in a dust free chamber to make collagen film. This film is cut into shape to obtain insert, which is subjected to crosslinking with UV irradiation followed by conventional sterilization. The prepared inserts are very effective for temporary punctal occlusion in various corneal conditions and are very effective to treat dry eye syndrome due to occupational conditions. Thus, collagen was isolated from Achilles tendons of cow using the scouring solns. containing sodium lauryl sulfate, succinylated at pH 9.0, and mixed with polyethylene glycol and dexamethasone to obtain a viscoelastic solution for ophthalmic applications. The solution was air dried at 15°, made into ophthalmic inserts, the inserts were crosslinked by exposure to UV irradiation, sterilized by ethylene oxide fumigation, and doubly packed.

L4 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1431601 CAPLUS
DOCUMENT NUMBER: 150:10981
TITLE: Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Zlatkis, Ella; Berman, Tal; Schuz, David
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 100pp., Cont.-in-part of U.S. Ser. No. 14,088.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 33
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080292560	A1	20081127	US 2008-49203	20080314
US 20080299220	A1	20081204	US 2008-14088	20080114
PRIORITY APPLN. INFO.:			US 2007-880434P	P 20070112
			US 2007-918025P	P 20070314
			US 2007-919303P	P 20070321
			US 2008-14088	A2 20080114
			US 2003-492385P	P 20030804
			US 2003-530015P	P 20031216
			US 2004-835505	A2 20040428
			US 2004-911367	A2 20040804
			US 2005-679020P	P 20050509
			US 2006-784793P	P 20060321
			US 2006-430599	A2 20060509
			US 2006-861620P	P 20061129
			US 2007-653205	A2 20070112
			US 2007-947751	A2 20071129

AB A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixts. thereof; 0% to about 48% of at least one secondary solvent; and an accommodating agent or complex; and methods of treatment are claimed. A hygroscopic silicone in glycol containing composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and a therapeutic agent. A foam composition contained polyethylene glycol-200 76.00, aluminum starch octynylsuccinate 4.00, cetearyl alc. 2.00, cetearyl alc. and cetearyl glucoside 2.00, cyclomethicone (Dow Corning 345 Silicone Fluid) 2.00, stearic acid foam 4.00, steareth-2 (Brij 72) 2.00, stearyl alc. 2.00, and vitamin C 8.00%. The propellant is a mixture of propane, butane and isobutane.

L4 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:555906 CAPLUS
DOCUMENT NUMBER: 148:546189
TITLE: Injectable hollow particulate tissue filler for tissue repair
INVENTOR(S): Chu, Jack Fa-De
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080107744	A1	20080508	US 2007-935210	20071105
PRIORITY APPLN. INFO.:			US 2006-864446P	P 20061106

AB The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective d. and are able to suspend in the carrier without precipitation. The loss of skin volume as a result of aging, diseases, weight loss, and injury can lead to uneven skin surface (e.g. wrinkle, etc.). The uneven skin can be repaired by injecting appropriate amount of hollow fillers underneath the skin. Some cases of urinary incontinence occur when the resistance to urine flow has decreased excessively. Continence is restored by injecting the present invention to the urethra tissue to increase resistance to urine outflow. Similarly, the present invention allows for the control of gastric fluid reflux by submucosal injections of the fillers to the esophageal-gastric and gastric-pyloric junction. For patients with vesicoureteral reflux, it can be treated by injection of the present invention into patients' ureteral tissue. This invention can also be used to repair defective or inadequately functioning muscles of the anal sphincter by administering an effective amount of injectable hollow fillers into the defect or anal sinuses.

L4 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:349028 CAPLUS
DOCUMENT NUMBER: 148:338999
TITLE: Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof for treatment of skin and other disorders
INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir; Berman, Tal; Schuz, David
PATENT ASSIGNEE(S): Foamix Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 57pp., Cont.-in-part of U.S. Ser. No. 430,599.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 33
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080069779	A1	20080320	US 2007-900072	20070910
US 20050031547	A1	20050210	US 2004-835505	20040428
AU 2004313285	A1	20050929	AU 2004-313285	20041216
US 20060275218	A1	20061207	US 2006-430599	20060509
AU 2006298442	A1	20070412	AU 2006-298442	20060509

CA 2609953	A1	20070412	CA 2006-2609953	20060509
WO 2007039825	A2	20070412	WO 2006-IB3628	20060509
WO 2007039825	A3	20080306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006313443	A1	20070518	AU 2006-313443	20060509
CA 2610662	A1	20070518	CA 2006-2610662	20060509
WO 2007054818	A2	20070518	WO 2006-IB3519	20060509
WO 2007054818	A3	20081023		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1888032	A2	20080220	EP 2006-831721	20060509
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
EP 1893396	A2	20080305	EP 2006-809259	20060509
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008540508	T	20081120	JP 2008-510676	20060509
JP 2008540511	T	20081120	JP 2008-510679	20060509
US 20070280891	A1	20071206	US 2006-645444	20061226
US 20080050317	A1	20080228	US 2007-894668	20070820
MX 2007014106	A	20080829	MX 2007-14106	20071109
IN 2007KN04432	A	20080125	IN 2007-KN4432	20071203
IN 2007KN04590	A	20080704	IN 2007-KN4590	20071203
PRIORITY APPLN. INFO.:			US 2003-492385P	P 20030804
			US 2003-530015P	P 20031216
			US 2004-835505	A2 20040428
			US 2005-679020P	P 20050509
			US 2006-784793P	P 20060321
			US 2006-430599	A2 20060509
			US 2006-843140P	P 20060908
			WO 2006-IB3519	W 20060509
			WO 2006-IB3628	W 20060509

AB Vitamin and flavonoid containing compns. are provided that are stable to degradation. Stabilized compns. include one or more features including a hygroscopic solvent at a sufficient concentration to provide an Aw value of the hygroscopic vitamin and or flavonoid containing composition of less than 0.9, antioxidant flavonoids that are preferentially oxidized before the vitamin, preservatives, and hydrocarbon propellants selected to reduce the oxidation potential of the composition. Thus, a foamable carrier was prepared containing

propylene glycol 88.00, stearyl alc. 2.00, hydroxypropyl cellulose 2.00, Laureth-4 2.00, GMS NE 2.00, macrogol cetostearyl ether 1.00, and PPG-15 stearyl ether 3.00%, resp. Ascorbic acid and niacinamide were concurrently added to the carrier at 5.00% and 2.00%, resp. Following addition of a propellant, the foamable composition was obtained, which upon release from an aerosol pressurized container afforded foam of good quality. The foam was easily spread and immediately absorbed into the facial skin with no extensive rubbing.

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:226051 CAPLUS
DOCUMENT NUMBER: 148:269446
TITLE: Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David
PATENT ASSIGNEE(S): Foamix Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 33
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080044444	A1	20080221	US 2007-825406	20070705
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050031547	A1	20050210	US 2004-835505	20040428
US 20050069566	A1	20050331	US 2004-911367	20040804
AU 2004313285	A1	20050929	AU 2004-313285	20041216
US 20050232869	A1	20051020	US 2005-78902	20050311
ZA 2005003298	A	20060830	ZA 2005-3298	20050425
US 20060140984	A1	20060629	US 2005-532618	20051222
AU 2006201878	A1	20070927	AU 2006-201878	20060504
US 20070280891	A1	20071206	US 2006-645444	20061226
US 20070292461	A1	20071220	US 2007-653205	20070112
US 20070253911	A1	20071101	US 2007-717897	20070313
WO 2008038147	A2	20080403	WO 2007-IB3759	20070705
WO 2008038147	A3	20081016		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,			

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 US 20080050317 A1 20080228 US 2007-894668 20070820
 PRIORITY APPLN. INFO.: IL 2002-152486 A 20021025

US 2002-429546P P 20021129
 US 2003-492385P P 20030804
 WO 2003-IB5527 W 20031024
 US 2003-530015P P 20031216
 US 2004-835505 A2 20040428
 US 2004-911367 A2 20040804
 US 2005-78902 A2 20050311
 US 2005-532618 A2 20051222
 US 2006-818634P P 20060705
 US 2007-653205 A2 20070112
 US 2007-717897 A2 20070313
 US 2005-679020P P 20050509
 US 2006-781868P P 20060313
 US 2006-784793P P 20060321
 US 2006-430599 A2 20060509
 US 2007-897638P P 20070126
 US 2007-899176P P 20070202

AB The present invention relates to a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixts. thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixts. thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a

liquefied hydrocarbon gas propellant. Thus, a foaming vehicle composition comprised (i) an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.00, oleyl alc. 20.00, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol 17.70, and water 30.00%, resp.

L4 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:96437 CAPLUS
 DOCUMENT NUMBER: 148:175777
 TITLE: Compositions and methods for dermally treating neuropathy with minoxidil
 INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17pp., Cont.-in-part of U.S. Ser. No. 640,139.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080019927	A1	20080124	US 2007-888905	20070801
US 20050276842	A1	20051215	US 2005-146917	20050606
US 20070189980	A1	20070816	US 2006-640135	20061214
US 20070196458	A1	20070823	US 2006-640139	20061214
AU 2006339350	A1	20070907	AU 2006-339350	20061214

CA 2633464 A1 20070907 CA 2006-2633464 20061214
 EP 1968541 A2 20080917 EP 2006-849969 20061214
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, RS
 IN 2008MN01481 A 20081010 IN 2008-MN1481 20080714
 WO 2009017767 A2 20090205 WO 2008-US9222 20080730
 W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 CN 101370453 A 20090218 CN 2006-80052642 20080811
 PRIORITY APPLN. INFO.: US 2004-577536P P 20040607
 US 2005-146917 A2 20050606
 US 2005-750519P P 20051214
 US 2005-750637P P 20051214
 US 2006-640135 A2 20061214
 US 2006-640139 A2 20061214
 US 2005-750521P P 20051214
 WO 2006-US48059 W 20061214
 US 2007-888905 A 20070801

AB The present invention is drawn to adhesive solidifying formulations containing minoxidil that can be used for treating neuropathies including diabetic neuropathy. The formulation can include an amount of minoxidil, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the minoxidil at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated

L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:86833 CAPLUS
 DOCUMENT NUMBER: 148:387369
 TITLE: Method for manufacturing nanofiber nonwoven fabrics containing antioxidant as wound dressing
 INVENTOR(S): Lee, Seong Jun; Lee, Se Geun; Kim, Ho Yeong; Kim, Jae Ryong; Cha, Yeong; Ryu, Won Seok
 PATENT ASSIGNEE(S): Daegu Gyeongbuk Institute of Science and Technology, S. Korea; Yeungnam University, Industry-Academy Cooperation Foundation
 SOURCE: Repub. Korea, 9pp.
 CODEN: KRXXFC
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 791039	B1	20080103	KR 2006-71624	20060728

PRIORITY APPLN. INFO.: KR 2006-71624 20060728

AB The title nanofiber nonwoven fabrics contain N-acetyl-L-cysteine (NAC)-impregnated biocompatible polymer. The title method comprises dissolving the biocompatible polymer in solvent, adding NAC-containing solution in the polymer solution, and carrying out elec. radiation on the mixed solution. The nonwoven fabrics have good softness, fine pores, large sp. surface area, good adhesion to the skin, and excellent air permeability, and can be used as wound dressings. The nonwoven fabrics can inhibit infection caused by the penetration of external bacteria. With the antioxidant, the generation of active oxygen species is inhibited, so that cells of damaged tissues can be regenerated effectively.

L4 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1259890 CAPLUS

DOCUMENT NUMBER: 149:541538

TITLE: Method for preparing taxanes tumor-targeting sustained-release gel injection for treating solid tumors

INVENTOR(S): Hou, Hongtao; Sun, Qiming

PATENT ASSIGNEE(S): Jinan Jifu Pharmtech Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 14pp.
CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 101283976	A	20081015	CN 2008-10301835	20080530
PRIORITY APPLN. INFO.:			CN 2008-10301835	20080530

AB The title tumor-targeting sustained-release gel injection containing taxanes for treating various solid tumors is prepared from 0.005-4% taxanes drug, amphiphilic block copolymer, solvent, and drug release regulator. In the gel injection, taxanes are completely or partly embedded in sustained-release microspheres, the solvent is selected from distilled water, water for injection, physiol. buffer, cell culture fluid, body fluid, tissue fluid, buffer, and phosphate buffer, and the content of solvent in the hydrogel comprising solvent and amphiphilic block copolymer is 60-99%. The taxanes drug is selected from docetaxel, taxol, epitaxol, hydroxytaxol, and deacetyltaxol. The amphiphilic block copolymer comprises polyethylene glycol and polyester, including polylactic acid-polyethylene glycol-poly(lactic acid), poly(glycolide-co-lactide)-polyethylene glycol-poly(lactic acid), poly(glycolide-co-lactide)-poly(lactic acid)-polyethylene glycol, and poly(lactic acid)-polyethylene glycol-poly(glycolide-co-lactide)-poly(lactic acid). The drug release regulator is selected from one or more of sugar, salt, CMC-Na, glycerol, dimethylsilicone oil, propanediol, carbomer, mannitol, surfactants, etc. 6 kinds of methods for preparing the gel injection are presented in the invention. In the gel injection, the mixture of amphiphilic block copolymer and solvent has temperature-sensitive gelation characteristics and can be transformed into a stagnant, biodegradable, and insol. gel in vivo, which can sustain local drug release in tumor in several wk to several mo. The prepared gel injection can be used for treating various tumors at different stages and tumors which could not be resected, controlling tumor-related complications and recurrence of post-operational residual tumor, and enhancing chemotherapeutic effects and radiotherapeutic effects.

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:988451 CAPLUS

DOCUMENT NUMBER: 149:333445
 TITLE: Pressure sensitive adhesive containing hydroxy acid oligomer with good water absorption and elasticity and its application
 INVENTOR(S): Dong, Anjie; Li, Jun; Deng, Liandong
 PATENT ASSIGNEE(S): Tianjin University, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 9pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101240149	A	20080813	CN 2007-10056733	20070207
PRIORITY APPLN. INFO.:			CN 2007-10056733	20070207

AB Title adhesive consists of (A) N-vinylpyrrolidone and its alkyl substituted derivative (co)polymer, polyacrylic acid, polyacrylamide, polyamino acid, polymethacrylic acid, polyvinyl alc., etc., with relative mol. weight (10-20) x 10⁴ 30-70, (B) oligomer or copolymer of lactic acid, glycolic acid, hydroxybutyric acid, or caprolactone with polymerization degree 2-8 10-40, (C) short chain polyol and/or amine with relative mol. weight ≤300 10-50, and (D) water 1-50%. The pressure sensitive adhesive, having good water absorption, elasticity, and adhesion, can be used for transdermal drug delivery system, treatment of skin diseases, cosmetic and skin care.

L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:200433 CAPLUS
 DOCUMENT NUMBER: 146:258990
 TITLE: Methods and devices for lymphatic targeting
 INVENTOR(S): Liu, Jiang; Johnston, Michael Richard; Wu, Xiao Yu
 PATENT ASSIGNEE(S): University Health Network, Can.
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007019678	A1	20070222	WO 2006-CA1321	20060814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2618807 A1 20070222 CA 2006-2618807 20060814 EP 1922094 A1 20080521 EP 2006-775100 20060814 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR IN 2008DN02108 A 20080711 IN 2008-DN2108 20080311 CN 101287507 A 20081015 CN 2006-80038249 20080414				

PRIORITY APPLN. INFO.:

US 2005-707534P

P 20050812

WO 2006-CA1321

W 20060814

AB The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to methods of using and the process of preparing, the implantable device. Therapeutic effects of PLGA-paclitaxel gelatin sponge in controlling lymphatic tumor in an orthotopic adjuvant lung cancer model in nude rats was shown. Intraoperative implantation of gelatin sponge containing PLGA-paclitaxel significantly reduced lymphatic tumor metastasis. The incidence of lymphatic metastasis was significantly lower in the treatment group 25% (2/8) compared to the controls 100% (8/8) (p<0.01).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1450675 CAPLUS

DOCUMENT NUMBER: 148:85686

TITLE: Polypropylene glycol foamable vehicle and pharmaceutical compositions

INVENTOR(S): Friedman, Doron; Tamarkin, Dov; Feiman, Naomi; Schuz, David; Berman, Tal

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 33

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070292359	A1	20071220	US 2007-811140	20070607
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050031547	A1	20050210	US 2004-835505	20040428
US 20050069566	A1	20050331	US 2004-911367	20040804
US 20050074414	A1	20050407	US 2004-922358	20040820
AU 2004313285	A1	20050929	AU 2004-313285	20041216
US 20050232869	A1	20051020	US 2005-78902	20050311
ZA 2005003298	A	20060830	ZA 2005-3298	20050425
US 20050271596	A1	20051208	US 2005-124676	20050509
US 20060140984	A1	20060629	US 2005-532618	20051222
AU 2006201878	A1	20070927	AU 2006-201878	20060504
US 20070020304	A1	20070125	US 2006-481596	20060706
WO 2007085899	A2	20070802	WO 2006-IB4026	20060706
WO 2007085899	A3	20080710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
 US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 US 20070020213 A1 20070125 US 2006-488989 20060719
 WO 2007085902 A2 20070802 WO 2006-IB4119 20060719
 WO 2007085902 A3 20071129
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
 US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 US 20070280891 A1 20071206 US 2006-645444 20061226
 US 20070253911 A1 20071101 US 2007-717897 20070313
 US 20080050317 A1 20080228 US 2007-894668 20070820
 US 20080152596 A1 20080626 US 2007-894767 20070820
 PRIORITY APPLN. INFO.:
 IL 2002-152486 A 20021025
 US 2002-429546P P 20021129
 US 2003-492385P P 20030804
 US 2003-497648P P 20030825
 WO 2003-IB5527 W 20031024
 US 2003-530015P P 20031216
 US 2004-835505 A2 20040428
 US 2004-911367 A2 20040804
 US 2004-922358 A2 20040820
 US 2005-78902 A2 20050311
 US 2005-124676 A2 20050509
 US 2005-696878P P 20050706
 US 2005-700702P P 20050719
 US 2005-532618 A2 20051222
 US 2006-781868P P 20060313
 US 2006-811627P P 20060607
 US 2006-481596 A2 20060706
 US 2006-488989 A2 20060719
 US 2007-897638P P 20070126
 US 2007-899176P P 20070202
 US 2007-717897 A2 20070313
 US 2007-811140 A1 20070607
 AB The present invention relates to a foamable pharmaceutical carrier
 comprising polypropylene glycol (PPG) alkyl ether, a surfactant, water and
 a liquefied hydrocarbon gas propellant; and pharmaceutical compns.
 thereof. The present invention further teaches a foamable pharmaceutical
 carrier comprising PPG alkyl ether, a surfactant, and a liquefied
 hydrocarbon gas propellant; and pharmaceutical compns. thereof.
 L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:941796 CAPLUS
 DOCUMENT NUMBER: 147:308196
 TITLE: Adhesive solidifying formulations for treating

INVENTOR(S): dermatitis or psoriasis
 PATENT ASSIGNEE(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay
 SOURCE: USA
 U.S. Pat. Appl. Publ., 20pp., Cont.-in-part of U.S.
 Ser. No. 146,917.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070196459	A1	20070823	US 2006-640140	20061214
US 20050276842	A1	20051215	US 2005-146917	20050606
AU 2006339350	A1	20070907	AU 2006-339350	20061214
CA 2633464	A1	20070907	CA 2006-2633464	20061214
EP 1968541	A2	20080917	EP 2006-849969	20061214
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
IN 2008MN01481	A	20081010	IN 2008-MN1481	20080714
CN 101370453	A	20090218	CN 2006-80052642	20080811
PRIORITY APPLN. INFO.:				
			US 2004-577536P	P 20040607
			US 2005-146917	A2 20050606
			US 2005-750524P	P 20051214
			US 2005-750637P	P 20051214
			US 2005-750521P	P 20051214
			WO 2006-US48059	W 20061214

AB The present invention is drawn to adhesive solidifying formulations for treating skin disorders, such as dermatitis or psoriasis. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein the non-volatile solvent system is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. A formulation contains polyvinyl alc., water, glycerol, propylene glycol, Gantrez ES 425, oleic acid, ethanol, and clobetasol propionate.

L4 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:941797 CAPLUS
 DOCUMENT NUMBER: 147:308197
 TITLE: Adhesive solidifying formulations for dermally treating neuropathic pain
 INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 22pp., Cont.-in-part of U.S.
 Ser. No. 146,917.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070196458	A1	20070823	US 2006-640139	20061214

US 20050276842	A1	20051215	US 2005-146917	20050606
AU 2006339350	A1	20070907	AU 2006-339350	20061214
CA 2633464	A1	20070907	CA 2006-2633464	20061214
EP 1968541	A2	20080917	EP 2006-849969	20061214
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080019927	A1	20080124	US 2007-888905	20070801
IN 2008MN01481	A	20081010	IN 2008-MN1481	20080714
CN 101370453	A	20090218	CN 2006-80052642	20080811

PRIORITY APPLN. INFO.:

US 2004-577536P	P	20040607
US 2005-146917	A2	20050606
US 2005-750519P	P	20051214
US 2005-750637P	P	20051214
US 2005-750521P	P	20051214
US 2006-640135	A2	20061214
US 2006-640139	A2	20061214
WO 2006-US48059	W	20061214

AB The present invention is drawn to adhesive solidifying formulations for treating neuropathic pain. The formulation can include a drug suitable for treating neuropathic pain, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. A formulation contains ropivacaine-HCl, Eudragit RL-100, ethanol, isostearic acid, glycerol, propylene glycol, and trolamine.

L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1226536 CAPLUS

DOCUMENT NUMBER: 145:511707

TITLE: Depot for sustained and controlled delivery of methotrexate

INVENTOR(S): Freier, Thomas; Montenegro, Rivelino; Shoichet, Molly S.

PATENT ASSIGNEE(S): Matrogen Corp., Can.

SOURCE: PCT Int. Appl., 95pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006122414	A1	20061123	WO 2006-CA805	20060517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-681729P P 20050517

AB An implantable device for sustained and controlled delivery of methotrexate in treating cancer, severe psoriasis and rheumatoid arthritis, and a method for producing a hydrogel casing using centrifugal forces are disclosed. The device with a variety of hollow structures and morphologies was produced with a rotational spinning technique using an aminated glass tube as the mold. Hydrogel tubes were made from a methacrylate monomer mixture and loaded with methotrexate and polycaprolactone as a stabilizer.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1066830 CAPLUS

DOCUMENT NUMBER: 145:404382

TITLE: Device and methods for treating paranasal sinus conditions

INVENTOR(S): Eaton, Donald J.; Tice, Thomas R.; Downie, David B.; Arensdorf, Patrick A.; Brenneman, Rodney; Biggs, Danielle L.

PATENT ASSIGNEE(S): Sinexus, Inc., USA

SOURCE: PCT Int. Appl., 82pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006107957	A2	20061012	WO 2006-US12484	20060404
WO 2006107957	A3	20061116		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006231506	A1	20061012	AU 2006-231506	20060404
CA 2603081	A1	20061012	CA 2006-2603081	20060404
US 20070005094	A1	20070104	US 2006-398342	20060404
EP 1871383	A2	20080102	EP 2006-749235	20060404
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2008537695	T	20080925	JP 2008-505446	20060404
IN 2007KN03661	A	20080328	IN 2007-KN3661	20070927
MX 2007012324	A	20080212	MX 2007-12324	20071003
KR 2008005939	A	20080115	KR 2007-725552	20071102
CN 101189016	A	20080528	CN 2006-80019539	20071203

PRIORITY APPLN. INFO.: US 2005-668569P P 20050404
WO 2006-US12484 W 20060404

AB Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus

inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:491792 CAPLUS

DOCUMENT NUMBER: 145:14124

TITLE: Topical delivery system comprising esters of hydroxy acids for cosmetic and pharmaceutical agents

INVENTOR(S): Gupta, Shyam K.

PATENT ASSIGNEE(S): Bioderm Research, USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060110415	A1	20060525	US 2004-904665	20041122
US 20070166255	A1	20070719	US 2007-670942	20070202
PRIORITY APPLN. INFO.:			US 2004-904665	A2 20041122
			US 2005-161856	A2 20050819

AB This invention relates to topical compns. containing esters of hydroxy acids and their application in the deep-penetration delivery of beneficial cosmetic and pharmaceutical agents. An ester of a hydroxy acid is selected from alkyl and aryl esters of glycolic, malic, lactic, mandelic, ascorbic, phytic, salicylic, aleuritic, and tartaric acids, etc. Thus, a skin whitening serum was prepared containing Et lactate 20.0, hydroxypropyl guar 0.5,, quinacetophenone 5.0, PEG-6 70.0, arbutin 4.0, and preservatives 0.5 parts, resp. The product had a clear to slightly hazy serum-like appearance. It was absorbed rapidly with a silky smooth skin feel. Also, an arthritis pain relief anti-inflammatory gel was prepared containing tri-Et citrate 55.65, Polyamide-3 5.0, preservative

0.5, Boswellia serrata extract 0.05, N-acetylglucosamine 2.0, methylsulfonylmethane 5.0, Aloe vera 0.1, vitamin E 0.5, paeonol 0.5, magnolol 0.2, chondroitin sulfate 0.5, and zeolite 30.0 parts, resp.

L4 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:591976 CAPLUS

DOCUMENT NUMBER: 143:120594

TITLE: Biocompatible protein particles and particle devices

INVENTOR(S): Masters, David B.; Berg, Eric P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 160,424.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050147690	A1	20050707	US 2004-962984	20041012
AU 2005295112	A1	20060420	AU 2005-295112	20051012
CA 2583561	A1	20060420	CA 2005-2583561	20051012
WO 2006042310	A1	20060420	WO 2005-US36867	20051012

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
HR, IS, YU

BR 2004016255	A	20070109	BR 2004-16255	20041112
CN 1902229	A	20070124	CN 2004-80039948	20041112
JP 2007510435	T	20070426	JP 2006-539948	20041112
IN 2006DN02640	A	20070810	IN 2006-DN2640	20060510
KR 2006123148	A	20061201	KR 2006-709221	20060511
MX 2006005469	A	20060725	MX 2006-5469	20060512

PRIORITY APPLN. INFO.:
US 2003-706689 A 20031112
WO 2004-US37971 W 20041112

AB The authors disclose IL-18 binding proteins, particularly human antibodies that bind human interleukin-18 (hIL-18). Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

L4 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:41238 CAPLUS
DOCUMENT NUMBER: 140:99289
TITLE: Skin compositions containing organic acids
and nonionic water-soluble polymers for external use
INVENTOR(S): Hanano, Akinori
PATENT ASSIGNEE(S): Noevir Co., Ltd., Japan
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004675	A1	20040115	WO 2003-JP101	20030109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003201853	A1	20040123	AU 2003-201853	20030109
JP 3907659	B2	20070418	JP 2004-519194	20030109
US 20060013786	A1	20060119	US 2005-520037	20050630

PRIORITY APPLN. INFO.:
JP 2002-193944 A 20020702
WO 2003-JP101 W 20030109

AB It is intended to provide skin preps. for external use having a pH value of ≤ 2 which can be uniformly spread out on the skin surface and have excellent efficaciousness and storage stability. Namely, disclosed are skin preps. for external use having a pH value of ≤ 2 which contain one or more organic acids and one or more nonionic water-soluble polymers other than polysaccharides. The composition is suitable for use for chemical peeling treatment of skin. A composition containing 70 % glycolic acid solution 30, 2 % high-mol.-weight polyoxyethylene glycol solution 25 % was formulated.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:739961 CAPLUS
DOCUMENT NUMBER: 141:248734
TITLE: Injectable sustained release pharmaceutical delivery devices
INVENTOR(S): Chou, Kang-Jye; Guo, Hong; Ashton, Paul; Shimizu, Robert W.; Watson, David A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 428,214.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040176341	A1	20040909	US 2003-714549	20031113
US 20040009222	A1	20040115	US 2003-428214	20030502
AU 2004292957	A1	20050609	AU 2004-292957	20041026
CA 2545650	A1	20050609	CA 2004-2545650	20041026
WO 2005051234	A2	20050609	WO 2004-US35430	20041026
WO 2005051234	A3	20051110		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1696822	A2	20060906	EP 2004-796413	20041026
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1901850	A	20070124	CN 2004-80040139	20041026
JP 2007512248	T	20070517	JP 2006-539545	20041026
MX 2006005431	A	20070125	MX 2006-5431	20060512
IN 2006DN02692	A	20070803	IN 2006-DN2692	20060512
NO 2006002362	A	20060813	NO 2006-2362	20060523
AU 2006202338	A1	20060622	AU 2006-202338	20060601
AU 2006202338	B2	20080918		
US 20080063687	A1	20080313	US 2007-894694	20070820
PRIORITY APPLN. INFO.:			US 2002-377974P	P 20020507
			US 2002-425943P	P 20021113
			US 2002-437576P	P 20021231
			US 2003-452348P	P 20030306
			US 2003-428214	A2 20030502
			AU 2001-253675	A3 20010419
			US 2003-714549	A 20031113
			US 2004-543368P	P 20040209
			WO 2004-US35430	W 20041026

AB An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as "coatings," "skins," or "outer layers"). In certain embodiments, the device is formed by

extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles. The device may be formed by combining at least one polymer, at least one drug, and at least one liquid solvent to form a liquid suspension or solution wherein, upon injection, such suspension or solution under goes a phase change and forms a gel. The configuration may provide for controlled release of the drug(s) for an extended period. Sustained-release pharmaceutical injections comprising fluocinolone acetonide, polycaprolactone, poly(vinyl acetate) at a drug loading level of 40% are described.

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:960660 CAPLUS

DOCUMENT NUMBER: 138:19488

TITLE: Method and pharmaceutical compositions using anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases

INVENTOR(S): Hunter, William L.

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: U.S., 180 pp., Cont.-in-part of U.S. Appl. 2002 37,919.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6495579	B1	20021217	US 1998-88546	19980601
US 20020037919	A1	20020328	US 1997-980549	19971201
US 6515016	B2	20030204		
CA 2607067	A1	19980611	CA 1997-2607067	19971202
EP 1070502	A2	20010124	EP 2000-123557	19971202
EP 1070502	A3	20011017		
EP 1070502	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1090637	A2	20010411	EP 2000-123537	19971202
EP 1090637	A3	20010912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1092433	A2	20010418	EP 2000-123534	19971202
EP 1092433	A3	20010912		
EP 1092433	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002226399	A	20020814	JP 2001-401899	19971202
EP 1582210	A2	20051005	EP 2005-11601	19971202
EP 1582210	A3	20051012		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1679937	A	20051012	CN 2005-10054770	19971202
CN 101011576	A	20070808	CN 2006-10099927	19971202

CN 101195028	A	20080611	CN 2006-10099895	19971202
WO 9962510	A2	19991209	WO 1999-CA464	19990601
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,				
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				
TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020013298	A1	20020131	US 1999-368463	19990804
US 20020183380	A1	20021205	US 2002-67467	20020205
US 6689803	B2	20040210		
US 20030157187	A1	20030821	US 2002-172737	20020613
US 20050249770	A1	20051110	US 2005-102587	20050408
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		
US 20080113035	A1	20080515	US 2007-891651	20070810
US 20080153900	A1	20080626	US 2007-891661	20070810
PRIORITY APPLN. INFO.:			US 1996-32215P	P 19961202
			US 1997-63087P	P 19971024
			US 1997-980549	A2 19971201
			CA 1997-2273240	A3 19971202
			CN 1997-181581	A3 19971202
			CN 2005-10054770	A3 19971202
			EP 1997-945697	A3 19971202
			EP 2000-123537	A3 19971202
			JP 1998-524997	A3 19971202
			US 1998-88546	A 19980601
			US 1999-368463	B1 19990804
			US 1999-368871	A1 19990804
			US 2002-172737	B1 20020613
			AU 2004-200715	A3 20040220
			US 2005-102587	B1 20050408
AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising delivering to the site of inflammation an anti-microtubule agent (e.g. paclitaxel), or analog or derivative thereof.				
REFERENCE COUNT:	171	THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		
L4 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN				
ACCESSION NUMBER:	2002:39555 CAPLUS			
DOCUMENT NUMBER:	136:107223			
TITLE:	Cleansing articles for skin and/or hair			
INVENTOR(S):	Albacarys, Lourdes Dessus; Mcatee, David Michael; Deckner, George Endel			
PATENT ASSIGNEE(S):	The Procter & Gamble Company, USA			
SOURCE:	U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 65,991, abandoned.			
	CODEN: USXXAM			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	8			
PATENT INFORMATION:				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6338855	B1	20020115	US 1999-296334	19990422
PRIORITY APPLN. INFO.:			US 1996-738145	B2 19961025
			US 1996-738668	B1 19961025

US 1997-974033 B2 19971119
US 1998-65991 B2 19980424
US 1998-83015P P 19980424

AB The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair and delivering skin care actives onto the skin or hair. These articles are used by the consumer by wetting the dry article with water and generating lather by subjecting the wetted article to mech. forces, e.g., rubbing. The article comprises a water insol. substrate, a lathering surfactant, and a skin care active component. Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component. The following ingredients containing PEG 0.5 and water qs to 100%. To the above mixture was added disodium EDTA 0.10, sodium lauroyl sarcosinate 3.33, cocamidopropyl betaine 3.33, decyl polyglucoside 3.33, methylparaben 0.25, phenoxyethanol 0.3, and benzyl alc. 0.3%. The following components water 2.0, butylene glycol 2.0, and propylparaben 0.15% were added to the above surfactant mixture. A skin-care active composition containing sucrose esters with cotton fatty acids 48.00, sucrose ester with behenic acid 12.00, petrolatum 10.00, tribehenin 5.00, and C10-30 cholesterol/lanosterol esters 18.00% and was added to the surfactant mixture.

REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:63453 CAPLUS
DOCUMENT NUMBER: 136:123645
TITLE: Topical pharmaceutical patch compositions containing nonsteroidal antiinflammatory agents
INVENTOR(S): Seitai, Yang Poy; Cho, Seimin
PATENT ASSIGNEE(S): Sang-A Pharmaceutical Co., Ltd., S. Korea
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2002020274	A	20020123	JP 2000-175244	20000612
PRIORITY APPLN. INFO.:			JP 2000-175244	20000612

AB The invention relates to a topical pharmaceutical patch composition containing a

nonsteroidal antiinflammatory agent as an active ingredient, having excellent drug-releasing, transdermal absorption, and skin adhesive properties without causing skin irritation, wherein the composition contains nonsteroidal antiinflammatory agent 0.01-2, alkyl pyrrolidone 0.5-10, hydrophilic polyether 1-15, hydrophilic nonionic surfactant 0.01-5, carboxyl group-containing water-soluble polymer or its salt 2-15, water-soluble vinyl polymer 0.1-10, water-insol. polyvalent metal salt 0.01-10, polyalc. 5-50 %, organic hydroxyacid, and water. A plaster-type patch was prepared from ketoprofen 0.3, polysorbate 80 0.5, Me pyrrolidone 3, polyethylene glycol 10, sodium CM-cellulose 4, sodium polyacrylate 6, vinylpyrrolidone-vinyl acetate copolymer 4, dried aluminum hydroxide gel 0.2, Me paraben 0.1, EDTA-2Na 0.5, tartaric acid 2.2, glycerin 28, and water q.s. to 100 %.

L4 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:265288 CAPLUS
DOCUMENT NUMBER: 134:300844
TITLE: Hybrid matrices and hybrid matrix mixtures for

INVENTOR(S): delivering a polypeptide to an animal
 Mineau-Hanschke, Rochelle; Lamsa, Justin Chace;
 Abalos-Coyle, Deborah
 PATENT ASSIGNEE(S): Transkaryotic Therapies, Inc., USA
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024842	A2	20010412	WO 2000-US27362	20001004
WO 2001024842	A3	20010830		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6419920	B1	20020716	US 1999-413715	19991005
CA 2379971	A1	20010412	CA 2000-2379971	20001004
AU 2000078545	A	20010510	AU 2000-78545	20001004
AU 777833	B2	20041104		
BR 2000014503	A	20020611	BR 2000-14503	20001004
EP 1221937	A2	20020717	EP 2000-968669	20001004
EP 1221937	B1	20041215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511100	T	20030325	JP 2001-527841	20001004
NZ 518759	A	20041029	NZ 2000-518759	20001004
AT 284674	T	20050115	AT 2000-968669	20001004
IL 148962	A	20080708	IL 2000-148962	20001004
IN 2002MN00098	A	20060915	IN 2002-MN98	20020125
MX 2002001450	A	20020830	MX 2002-1450	20020211
HK 1047240	A1	20050624	HK 2002-108845	20021205
PRIORITY APPLN. INFO.:				
			US 1999-413715	A1 19991005
			US 2000-662037	A1 20000914
			US 1995-548002	A3 19951025
			US 1999-312246	A2 19990514
			WO 2000-US27362	W 20001004
AB	A composition having a body of matrix material made up of insol. collagen fibrils, and disposed there within: (a) a plurality of vertebrate cells; (b) a plurality of microcarriers; and (c) an agent such as a factor that promotes vascularization, a cytokine, a growth factor, or ascorbic acid. The invention also features a method of delivering a polypeptide to an animal. The method involves introducing into the animal a fluid mixture containing: (a) a population of cultured vertebrate cells genetically engineered to express the polypeptide; and (b) a plurality of microcarriers. Heparin-sepharose hybrid collagen matrixes were prepared The heparin-sepharose beads were coated with bFGF (50 µg/mL packed beads). The beads containing human foreskin fibroblast clone expressing hFVIII at level between 20,000-30,000 mU/24h/106 cells were s.c. implanted into mice. The amount of hFVIII production was significantly higher than uncoated matrixes.			
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:906235 CAPLUS
DOCUMENT NUMBER: 136:25166
TITLE: Method for composite cell-based implants using mineral or polymeric microcarriers
INVENTOR(S): Frondoza, Carmelita G.; Hungerford, David S.; Shikani, Alan H.; Domb, Abraham J.; Fink, David J.; Bloom, Leonard
PATENT ASSIGNEE(S): Chondros, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U. S. Ser. No. 825,632.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010051834	A1	20011213	US 2001-922909	20010806
US 20010014475	A1	20010816	US 2001-825632	20010404
US 20020012705	A1	20020131	US 2001-929697	20010814
US 6514522	B2	20030204		
US 20020123142	A1	20020905	US 2002-39718	20020103
US 20020133235	A1	20020919	US 2002-66992	20020204
US 20040117033	A1	20040617	US 2003-731366	20031209
PRIORITY APPLN. INFO.:			US 1998-81016P	P 19980408
			US 1998-104842P	P 19981020
			US 1999-275319	A2 19990324
			US 2000-712662	A2 20001114
			US 2001-825632	A2 20010404
			US 1999-165608P	P 19991115
			US 2000-228855P	P 20000829
			US 2001-922909	A3 20010806

AB This invention is a method for the implantation of a combination of cells or cell-microcarrier aggregates wherein one component comprises a solid implantable construct and a second component comprises an injectable formulation. For example, in one embodiment, the solid implant may be first implanted to fill the majority of the cavity receiving the implant, and then cells or cell-microcarrier aggregates in an injectable format, with or without the addition of gelling materials to promote rapid gelling in situ, may be injected into spaces surrounding the solid implant in order to secure the solid implant in the site and/or to promote rapid adherence and/or integration of the solid implant to surrounding tissues. Also contemplated in this embodiment is that the cellular composition of the injectable component may differ from that of the solid component. For example, the solid implant may result from the culturing of chondrocytes on microcarriers or scaffolds, e.g., calcium carbonate, calcium phosphate or calcium sulfate, biopolymers, or synthetic polymers such as polylactic acid, polyglycolic or their copolymers, thereby resulting in an implant having cartilage-like properties, whereas the injectable cells or aggregates may result from the culturing of stem cells, resulting thereby in cells capable of producing cells of a chondrogenic, fibroblastic, myoblastic or osteoblastic phenotype. In this example, cells in the injectable aggregates may promote the fixation to or rapid integration of the solid cartilage implant into surrounding cartilage, connective tissue, muscle or bone, resp. A method of treating a skin lesion or nose or ear defects comprises filling the lesion or defect with a solid cell-containing implant along with an injectable cell-containing formulation.

L4 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:297284 CAPLUS

DOCUMENT NUMBER: 130:329018
 TITLE: Cleansing and conditioning article for skin
 or hair having improved fragrance delivery
 INVENTOR(S): Hasenoehrl, Erik John; Gottlieb, Emily Elizabeth
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921532	A1	19990506	WO 1998-US22212	19981020
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2308005	A1	19990506	CA 1998-2308005	19981020
CA 2308005	C	20060103		
AU 9911079	A	19990517	AU 1999-11079	19981020
AU 735322	B2	20010705		
EP 1024785	A1	20000809	EP 1998-953803	19981020
EP 1024785	B1	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9815215	A	20001017	BR 1998-15215	19981020
JP 2001520983	T	20011106	JP 2000-517692	19981020
AT 230976	T	20030215	AT 1998-953803	19981020
ES 2191349	T3	20030901	ES 1998-953803	19981020
CN 1149070	C	20040512	CN 1998-811617	19981020
MX 2000004009	A	20001130	MX 2000-4009	20000425
PRIORITY APPLN. INFO.:			US 1997-957174	A 19971024
			WO 1998-US22212	W 19981020

AB The present invention relates to a substantially dry, disposable, personal cleansing product useful for both cleansing and conditioning the skin/hair and providing improved fragrance delivery. These articles are used by the consumer by wetting the dry article with water. The article comprises a water-insol. substrate, a lathering surfactant, and a fragrance-releasing complex. Preferably, the articles of the present invention further comprise a conditioning component. Use of the substrate enhances lathering at low surfactant levels, increases cleansing and exfoliation, optimizes delivery and deposition of conditioning ingredients, and provides desirable characteristics such as texture, thickness and bulk. As a result, this invention provides effective cleansing using low, and hence less irritating, levels of surfactant while providing superior conditioning benefits by using a substrate having desirable characteristics. The invention also encompasses products further comprising a coating material for encapsulating the fragrance-releasing complex. The invention also encompasses products comprising various active ingredients for delivery to the skin or hair. The invention also encompasses methods for manufacturing these products.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 122:17231
ORIGINAL REFERENCE NO.: 122:3405a,3408a
TITLE: Injection of liposomes for treatment of inflamed tissues
INVENTOR(S): Woodle, Martin C.; Martin, Francis J.; Huang, Shi K.
PATENT ASSIGNEE(S): Liposome Technology, Inc., USA
SOURCE: U.S., 36 pp. Cont.-in-part of U.S. Ser. No. 5,213,804.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5356633	A	19941018	US 1992-958100	19921007
US 5013556	A	19910507	US 1989-425224	19891020
AU 9066374	A	19910516	AU 1990-66374	19901019
AU 642679	B2	19931028		
EP 496813	A1	19920805	EP 1990-916409	19901019
EP 496813	B1	19941214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05505173	T	19930805	JP 1990-515238	19901019
JP 3571335	B2	20040929		
US 5213804	A	19930525	US 1991-642321	19910115
NO 9201213	A	19920604	NO 1992-1213	19920327
KR 134982	B1	19980422	KR 1992-700918	19920420
FI 9201763	A	19920421	FI 1992-1763	19920421
WO 9407466	A1	19940414	WO 1993-US9572	19931007
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9453231	A	19940426	AU 1994-53231	19931007
EP 662820	A1	19950719	EP 1993-923295	19931007
EP 662820	B1	19970507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 152614	T	19970515	AT 1993-923295	19931007
ES 2104184	T3	19971001	ES 1993-923295	19931007
CA 2146565	C	19981020	CA 1993-2146565	19931007
JP 10001431	A	19980106	JP 1997-63661	19970317
JP 2889549	B2	19990510		
JP 2001181214	A	20010703	JP 2001-4291	20010111
JP 3921050	B2	20070530		

PRIORITY APPLN. INFO.:
US 1989-425224 A2 19891020
US 1991-642321 A2 19910115
JP 1990-515238 A3 19901019
JP 1991-501034 A3 19901019
WO 1990-US6034 A 19901019
US 1992-958100 A 19921007
WO 1993-US9572 W 19931007

AB A liposomal composition for concentrating a therapeutic agent in an inflamed dermal

region is disclosed. The liposomes contain the therapeutic agent in an entrapped form and are composed of vesicle-forming lipids derivatized with hydrophilic biocompatible polymers. After i.v. administration, the liposomes are taken up by the inflamed region within 24-48 h, for site-specific release of entrapped compound into the inflamed region. For example, a lipid mixture containing PEG-distearoyl phosphatidylethanolamine conjugate, cholesterol sulfate, cholesterol, beclomethasone dipropionate was dissolved in MeOH/CHCl₃ mixture, lyophilized, and sonicated to prepare multilamellar vesicles. A suspension of the vesicles was extruded to produce liposomes in the size of 0.07-0.2 µm in diameter

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role

for nanomaterial substances
NEWS 27 MAR 23 CA/CAPplus enhanced with more than 250,000 patent
equivalents from China
NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:59:31 ON 30 MAR 2009

=> file caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'CAPLUS' ENTERED AT 14:59:41 ON 30 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:59:41 ON 30 MAR 2009

=> s glycolic acid and polyethylene glycol and peel?
L1 13 GLYCOLIC ACID AND POLYETHYLENE GLYCOL AND PEEL?

=> d l1 ibib abs 1-13

L1 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:138982 CAPLUS
DOCUMENT NUMBER: 150:199360
TITLE: Compositions and methods for dermally treating
neuropathy with minoxidil
INVENTOR(S): Sanjay, Sharma; Zhang, Jie; Warner, Kevin S.
PATENT ASSIGNEE(S): Zars Pharma, Inc., USA
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017767	A2	20090205	WO 2008-US9222	20080730
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20080019927 A1 20080124 US 2007-888905 20070801
 PRIORITY APPLN. INFO.: US 2007-888905 A 20070801
 US 2004-577536P P 20040607
 US 2005-146917 A2 20050606
 US 2005-750519P P 20051214
 US 2005-750637P P 20051214
 US 2006-640135 A2 20061214
 US 2006-640139 A2 20061214

AB The present invention is drawn to adhesive solidifying formulations containing minoxidil that can be used for treating neuropathies including diabetic neuropathy. The formulation can include an amount of minoxidil, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the minoxidil at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. Thus, a solidifying formulation for treating diabetic neuropathy and the associated neuropathic pain was prepared containing minoxidil 5, polyvinyl alc. 22.2, propylene glycol 22.2, ethanol 4.4, 5M HCl solution 1.8, and water 44.4%, resp. A solidified peel formulation was formed when the composition obtained was spread on a silicone-coated polyester release liner and the solidified peel was stretchable by 5% in one direction without cracking or splitting.

L1 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1377087 CAPLUS
 DOCUMENT NUMBER: 149:563462
 TITLE: Pharmaceutical controlled-release capsule with osmotic pump
 INVENTOR(S): Fu, Hongxing; Cao, Gaozhong; Wu, Mingchai; Huang, Peng; Zhou, Bitao; Pan, Rong; Zhao, Yingzheng; Yang, Wei; Li, Jianbo; Li, Xing; Wang, Yi
 PATENT ASSIGNEE(S): Wenzhou Medical College, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101301281	A	20081112	CN 2008-10062288	20080612
PRIORITY APPLN. INFO.:			CN 2008-10062288	20080612

AB The invention relates to an osmotic pump controlled-release capsule shell, which is composed of cap and shell body with pores (diameter 0.01-5 mm) for releasing drug. The materials of capsule shell contain controlled-release material 10-99.96, pore-forming agent 0.02-20, plasticizing agent 0.02-70 and other adjuvant proper amount. The controlled-release material is one or

more of Et cellulose, cellulose acetate, acrylic resin, polyethylene, polypropylene, polylactic acid, etc. The pore-forming agent is one or more of sodium chloride, potassium chloride, citric acid, sodium citrate, lactose, mannitol, etc. The plasticizing agent is one or more of glycerol, propanediol, PEG, tri-Et citrate, glycerol diacetate, etc. The method for preparing the capsule shell comprises dissolving materials in solvent, preparing preform by adhesive-dipping method, drying, preparing pores on the shell by laser, mech. or other methods, sealing the pores with water-soluble material, peeling, cutting and postprocessing.

L1 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:253740 CAPLUS
DOCUMENT NUMBER: 148:268985
TITLE: Skin peeling method using surface-active agents and acids
INVENTOR(S): Aubrun-Sonneville, Odile; Rathman Josserand, Michelle
PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Eur. Pat. Appl., 16pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1891928	A1	20080227	EP 2007-112735	20070719
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
FR 2905066	A1	20080229	FR 2006-53429	20060823
FR 2905066	B1	20081031		
US 20080051461	A1	20080228	US 2007-842342	20070821
JP 2008050358	A	20080306	JP 2007-216411	20070822
PRIORITY APPLN. INFO.:			FR 2006-53429	A 20060823
			US 2006-840957P	P 20060830

OTHER SOURCE(S): MARPAT 148:268985

AB A method of peeling skin comprises (a) topical application of a composition comprising (i) at least a hydroxy acid chosen from α -hydroxyacids, β -hydroxyacids α -keto-acids, β -keto-acids, and their mixture, (ii) at least 5% of a surfactant containing an alkyl chain having 6-16 carbon atom, (b) applying the composition on the skin, (c) and eventually washing off the composition from the skin. A skin peeling composition contained PEG-6-capric/caprylic glyceride 13, glycolic acid 20, and water q.s. 100%.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1470320 CAPLUS
DOCUMENT NUMBER: 148:77731
TITLE: Pullulan films and their use in edible packaging
INVENTOR(S): Shen, Shiji; Hoffman, Andrew J.; Harrison, Michael D.; Butler, Susan E.; Criswell, Erin S.; Patton, Penelope A.
PATENT ASSIGNEE(S): Tate & Lyle Ingredients Americas, Inc., USA
SOURCE: PCT Int. Appl., 60pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007149276	A2	20071227	WO 2007-US13841	20070613
WO 2007149276	A3	20080403		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20070292481	A1	20071220	US 2006-424586	20060616
US 20080152761	A1	20080626	US 2006-613365	20061220
AU 2007261567	A1	20071227	AU 2007-261567	20070613
EP 2037752	A2	20090325	EP 2007-777471	20070613
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2008DN10208	A	20090320	IN 2008-DN10208	20081210
PRIORITY APPLN. INFO.:			US 2006-424586	A 20060616
			US 2006-613365	A 20061220
			US 2007-910729P	P 20070409
			US 2007-912275P	P 20070417
			WO 2007-US13841	W 20070613

AB An edible article comprises a food product and a pullulan film that encloses the food product. The film may comprise a major amount of pullulan on a dry-solids basis, and a minor amount of at least two of glycerol, propylene glycol, sorbitol, and polyethylene glycol. Alternatively, the film may comprise a major amount of pullulan on a dry-solids basis, gelatin, and at least two of glycerol, propylene glycol, sorbitol, and polyethylene glycol, and may also comprise salt. The film may also comprise a first layer comprising a major amount of at least one food grade wax, a second layer comprising a major amount of pullulan and further comprise at least one plasticizer, and a third layer comprising at least one surfactant that is immiscible with aqueous pullulan compns. but which adheres to pullulan surfaces, wherein the surfactant is at least partially crystalline. The film may also comprise a major amount of pullulan on a dry-solids basis, at least one salt (and in some cases at least two salts), and at least one plasticizer. The film may comprise an edible film adhered to a peelable, flexible substrate, wherein the edible film comprises a major amount of pullulan on a dry-solids basis and at least one plasticizer. The edible article can be manufactured by preparing a film-forming composition, forming the film-forming composition into a film, and enclosing a food product with the film.

L1 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:993749 CAPLUS

DOCUMENT NUMBER: 147:330433

TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders

INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling

PATENT ASSIGNEE(S): Tristrata, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 15pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228
WO 2007103687	A2	20070913	WO 2007-US62975	20070228
WO 2007103687	A3	20081211		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1998788	A2	20081210	EP 2007-757636	20070228
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			

PRIORITY APPLN. INFO.: US 2006-778128P P 20060301
WO 2007-US62975 W 20070228

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

L1 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:670139 CAPLUS

DOCUMENT NUMBER: 147:79575

TITLE: Compositions comprising drugs, a solvent vehicle, and a solidifying agent for dermally treating pain

INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay

PATENT ASSIGNEE(S): Zars, Inc., USA

SOURCE: PCT Int. Appl., 84pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 19

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2007070679	A2	20070621	WO 2006-US47926	20061214
WO 2007070679	A3	20090108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006326018	A1	20070621	AU 2006-326018	20061214
CA 2633515	A1	20070621	CA 2006-2633515	20061214
AU 2006339350	A1	20070907	AU 2006-339350	20061214
CA 2633464	A1	20070907	CA 2006-2633464	20061214
EP 1959931	A2	20080827	EP 2006-848632	20061214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
EP 1968541	A2	20080917	EP 2006-849969	20061214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2008MN01481	A	20081010	IN 2008-MN1481	20080714
IN 2008MN01485	A	20081017	IN 2008-MN1485	20080714
CN 101370453	A	20090218	CN 2006-80052642	20080811
PRIORITY APPLN. INFO.:			US 2005-750519P	P 20051214
			US 2005-750637P	P 20051214
			US 2005-750683P	P 20051214
			US 2005-750521P	P 20051214
			WO 2006-US47926	W 20061214
			WO 2006-US48059	W 20061214

AB The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating pain, such as musculoskeletal pain, inflammation, joint pain, or neuropathic pain. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein the evaporation of at least some of the volatile solvent converts the formulation on the skin into a solidified layer and the non-volatile solvent system is capable of facilitating the topical delivery of the drug(s) at therapeutically effective rates over a sustained period of time. Using hairless mouse skin permeation expts., a formulation of ropivacaine, the non-volatile solvents glycerol and Tween 20 had low steady state flux values and would not be considered "flux-enabling", but mineral oil and isostearic acid are flux-enabling solvents and are good candidates for evaluation with solidifying agents and volatile solvents to design an acceptable peel formulation.

L1 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1289826 CAPLUS

DOCUMENT NUMBER: 146:107484

TITLE: Chinese medicinal composition of sustained release microsphere injection for restoring healthy energy and preparation methods thereof

INVENTOR(S): Zheng, Yongfeng; Fan, Lijun

PATENT ASSIGNEE(S): Tianjin Tasly Pharmaceutical Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 8pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1872262	A	20061206	CN 2005-10013674	20050603
PRIORITY APPLN. INFO.:			CN 2005-10013674	20050603

AB The title microspheres for injection are prepared from (wt%) Chinese medicinal extract 0.2-50, and one or more biodegradable polymers as medicinal adjuvants 50-99.8, wherein the polymers (such as lactide-glycolide copolymer, polylactic acid, and polyglycolic acid) have mol. weight of 5,000-1,000,000 Dalton. The Chinese medicinal extract is prepared from a composition developed on the base of known Huoxiangzhengqi Powder and comprising Rhizoma Atractylodis (Atractylodes lancea and/or Atractylodes chinensis) 80-240 g, Citrus reticulata (Pericarpium Citri Reticulatae) 80-240 g, Magnolia officinalis 80-240 g, Angelica dahurica 120-360 g, Poria cocos 120-360 g, Areca catechu peel 120-360 g, Pinellia ternate 80-240 g, Radix Glycyrrhizae extract 10-30 g, Pogostemon cablin oil 0.8-2.4 mL, and oil of Perilla frutescens leaf 0.4-2.0 mL. The inventive microspheres for injection have the advantages of controlled release and high bioavailability.

L1 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1282494 CAPLUS
 DOCUMENT NUMBER: 144:40380
 TITLE: Alcohol-based hand sanitizing composition
 INVENTOR(S): Brown, James Steven
 PATENT ASSIGNEE(S): James Steven Brown, USA
 SOURCE: Brit. UK Pat. Appl., 53 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2414666	A	20051207	GB 2004-12329	20040603
GB 2414666	B	20090107		
GB 2452189	A	20090225	GB 2008-21820	20040603
US 20050271595	A1	20051208	US 2005-102017	20050409
AU 2005327300	A1	20060817	AU 2005-327300	20050601
CA 2568888	A1	20060817	CA 2005-2568888	20050601
WO 2006085907	A2	20060817	WO 2005-US18992	20050601
WO 2006085907	A3	20061005		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,

KZ, MD, RU, TJ, TM
 EP 1765260 A2 20070328 EP 2005-856772 20050601
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU
 JP 2008508189 T 20080321 JP 2007-515471 20050601
 PRIORITY APPLN. INFO.: GB 2004-12329 A3 20040603
 US 2005-102017 A 20050409
 WO 2005-US18992 W 20050601

AB The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwashing composition comprising alc., water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin, e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colorings or UV markers. For example, a composition contained ethanol 62.0%, Carbopol ETD 2020 thickener 0.3%, diisopropanolamine 0.01%, disodium EDTA 0.01%, suspended particles Florasomes MXS Blue with fragrance and Fluorescent Brightener 236 0.5% and Florasomes MXS with triclosan 0.8%, and water to 100%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:979539 CAPLUS
 DOCUMENT NUMBER: 143:134879
 TITLE: Effect of chemical structure of urethane acrylate on adhesion promotion of waterborne primer for ethylene-vinyl acetate copolymer foam
 AUTHOR(S): Jeong, Han Mo; Yoon, Ku Sik; Park, Sung Jin; Kwon, Gun Ho; Kim, Yong Sung
 CORPORATE SOURCE: Department of Chemistry, University of Ulsan, Ulsan, 680-749, S. Korea
 SOURCE: Kongop Hwahak (2004), 15(6), 689-692
 CODEN: KOHWE9; ISSN: 1225-0112
 PUBLISHER: Korean Society of Industrial and Engineering Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: Korean

AB Effect of chemical structure of urethane acrylate on the adhesion promotion of waterborne UV-cure primer for ethylene vinyl acetate copolymer foam was studied. The urethane acrylate with higher hydrophobicity showed better adhesion promotion, which was achieved by increasing the content of soft segment and by lowering ionic content. When polycaprolactone diol type was used for soft segment, the improvement of adhesion was superior to the case of polybutylene adipate. With regard to the effect of ionic type, cationic urethane acrylate showed better adhesion promotion compared with anionic urethane acrylate.

L1 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:681176 CAPLUS
 DOCUMENT NUMBER: 141:195302
 TITLE: Skin peeling composition containing salicylic acid derivatives
 INVENTOR(S): Hansenne, Isabelle; Fares, Hani; Cornell, Marc; Foltis, Sidney P.
 PATENT ASSIGNEE(S): L'Oreal S.A., Fr.
 SOURCE: U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040161392	A1	20040819	US 2003-367952	20030219
WO 2004073605	A2	20040902	WO 2004-US1527	20040120
WO 2004073605	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601339	A2	20051207	EP 2004-703693	20040120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007227	A	20060131	BR 2004-7227	20040120
JP 2006518340	T	20060810	JP 2005-518836	20040120
US 20080146529	A1	20080619	US 2008-10897	20080131
PRIORITY APPLN. INFO.:			US 2003-367952	A 20030219
			WO 2004-US1527	W 20040120

OTHER SOURCE(S): MARPAT 141:195302

AB The present invention relates to methods of peeling skin using certain salicylic acid derivs., to chemical skin peel compns. containing these certain salicylic acid derivs. in a carrier, preferably a dermatol. acceptable carrier, to methods of making these compns., and methods of applying this certain compound and/or composition to skin to be peeled. For example, a skin-peeling composition contained 35% 5-n-octanoylsalicylic acid mixed with a blend of ethanol/propylene glycol.

L1 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:293236 CAPLUS

DOCUMENT NUMBER: 140:309413

TITLE: Solubility-enhanced β -hydroxycarboxylic acids for high-potency skin-peeling gels

INVENTOR(S): Cornell, Marc; Fares, Hani; Foltis, Sidney Peter; Hansenne, Isabelle

PATENT ASSIGNEE(S): Societe L'oreal S.A., Fr.

SOURCE: U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S. Provisional Ser. No. 416,259.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040067243	A1	20040408	US 2003-373102	20030226
BR 2003003931	A	20040908	BR 2003-3931	20031002
EP 1415654	A1	20040506	EP 2003-256282	20031006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
MX 2003009133	A	20040910	MX 2003-9133	20031006
JP 2004131503	A	20040430	JP 2003-347919	20031007
PRIORITY APPLN. INFO.:			US 2002-416259P	P 20021007
			US 2003-373102	A 20030226

AB The solubility in solvent media, notably alc. media, of the β -hydroxycarboxylic acids (BHAs), notably the chemical skin

peeling agent salicylic acid, is markedly enhanced by solubilizing same in the presence of at least one α -hydroxycarboxylic acid. Moreover, a higher potency skin-peeling products, due to the more concentrated BHA, are thus formulated to treat various skin problems. For example, a topical skin-peeling gel contained 32% salicylic acid as the active ingredient, 3% glycolic acid crystal as the solubilizer, 2% Klucel HF as the gelling agent and 63% ethanol as the solvent.

L1 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:41238 CAPLUS
DOCUMENT NUMBER: 140:99289
TITLE: Skin compositions containing organic acids and nonionic water-soluble polymers for external use
INVENTOR(S): Hanano, Akinori
PATENT ASSIGNEE(S): Noevir Co., Ltd., Japan
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004675	A1	20040115	WO 2003-JP101	20030109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003201853	A1	20040123	AU 2003-201853	20030109
JP 3907659	B2	20070418	JP 2004-519194	20030109
US 20060013786	A1	20060119	US 2005-520037	20050630
PRIORITY APPLN. INFO.:			JP 2002-193944	A 20020702
			WO 2003-JP101	W 20030109
AB It is intended to provide skin prepn. for external use having a pH value of ≤ 2 which can be uniformly spread out on the skin surface and have excellent efficaciousness and storage stability. Namely, disclosed are skin prepn. for external use having a pH value of ≤ 2 which contain one or more organic acids and one or more nonionic water-soluble polymers other than polysaccharides. The composition is suitable for use for chemical peeling treatment of skin. A composition containing 70 % glycolic acid solution 30, 2 % high-mol.-weight polyoxyethylene glycol solution 25 % was formulated.				
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L1 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:454385 CAPLUS
DOCUMENT NUMBER: 133:79034
TITLE: Chemical peeling compositions containing L-ascorbic acid derivatives and chemical peeling method
INVENTOR(S): Ito, Shinobu; Ogata, Eiji
PATENT ASSIGNEE(S): Showa Denko K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000186036	A	20000704	JP 1998-363316	19981221
PRIORITY APPLN. INFO.:			JP 1998-295169	A 19981016

OTHER SOURCE(S): MARPAT 133:79034

AB The compns., useful for treatment of wrinkle, spots, freckles, liver spot, acne, scars due to acne and burn, rough skin, pigmentation, decrease in elasticity of hair and nail, etc., contain chemical peeling agents, preferably, 2-hydroxycarboxylic acids or their derivs., and L-ascorbic acid (I) or its derivs. to prevent penetration of the agents to skin in depth and reduce skin irritation. A chemical peeling method involves application of a 1st agent containing chemical peeling agents to skin and application of a 2nd agent containing I or its derivs. once or several times before or after the 1st agents. A liquid containing sorbitol

4.0, dipropylene glycol 6.0, polyethylene glycol 1500 5.0, polyoxyethylene oleyl ether 0.5, Me cellulose 0.2, citric acid 0.01, NaOH, Na L-ascorbic acid 2-phosphate 5.0, Na dl- α -tocopherol phosphate 0.5, glycolic acid 1.0, Cl3CCO2H 1.0%, and H2O balance was prepared Antiwrinkle effect and skin irritation-inducing action of the composition was examined in 100 volunteers.

=> FIL STNGUIDE
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
51.60	51.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-10.66	-10.66

FILE 'STNGUIDE' ENTERED AT 15:01:34 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 27, 2009 (20090327/UP).

=>
Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	21	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China
NEWS	22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	24	APR 07	STN is raising the limits on saved answers
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.			
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:16:16 ON 14 APR 2009

=> file caplus medline
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:16:24 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:16:24 ON 14 APR 2009

=> s hanano a?/au
L1 48 HANANO A?/AU

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 46 DUP REM L1 (2 DUPLICATES REMOVED)

=> s l2 and py<=2002
L3 9 L2 AND PY<=2002

=> s l3 ibib abs 1-9
MISSING OPERATOR L3 IBIB
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l3 ibib abs 1-9

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:795661 CAPLUS

DOCUMENT NUMBER: 138:85503

TITLE: Stereochemical features of the hydrolysis of
9,10-epoxystearic acid catalysed by plant and
mammalian epoxide hydrolases

AUTHOR(S): Summerer, Stephan; Hanano, Abdulsamie;
Utsumi, Shigeru; Arand, Michael; Schuber, Francis;
Blee, Elizabeth

CORPORATE SOURCE: Laboratoire des Phytooxylipines, IBMP-CNRS-UPR 2357,
Strasbourg, 67 083, Fr.

SOURCE: Biochemical Journal (2002), 366(2), 471-480
CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cis-9,10-Epoxystearic acid was used as a tool to probe the active sites of
epoxide hydrolases (EHs) of mammalian and plant origin. We have compared
the stereochem. features of the hydrolysis of this substrate catalyzed by
soluble and membrane-bound rat liver EHs, by soluble EH (purified to apparent
homogeneity) obtained from maize seedlings or celeriac roots, and by
recombinant soybean EH expressed in yeast. Plant EHs were found to differ
in their enantioselectivity, i.e. their ability to discriminate between
the two enantiomers of 9,10-epoxystearic acid. For example, while the
maize enzyme hydrated both enantiomers at the same rate, the EH from
soybean exhibited very high enantioselectivity in favor of
9R,10S-epoxystearic acid. This latter enzyme also exhibited a strict
stereoselectivity, i.e. it hydrolyzed the racemic substrate with a very
high enantioconvergence, yielding a single chiral diol product,
threo-9R,10R-dihydroxystearic acid. Soybean EH shared these distinctive
stereochem. features with the membrane-bound rat liver EH. The
stereochem. outcome of these enzymes probably results from a

stereoselective attack by the nucleophilic residue on the oxirane ring carbon having the (S)-configuration, leading to the presumed (in plant EH) covalent acyl-enzyme intermediate. In sharp contrast, the reactions catalyzed by cytosolic rat liver EH exhibited a complete absence of enantioselectivity and enantioconvergence; this latter effect might be ascribed to a regioselective formation of the acyl-enzyme intermediate involving C-10 of 9,10-epoxystearic acid, independent of its configuration. Thus, compared with soybean EH, the active site of rat liver soluble EH displays a very distinct means of anchoring the oxirane ring of the fatty acid epoxides, and therefore appears to be a poor model for mapping the catalytic domain of plant EHs.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:129056 CAPLUS
DOCUMENT NUMBER: 136:189098
TITLE: Skin-moisturizing cosmetics for massage
INVENTOR(S): Hanano, Akinori
PATENT ASSIGNEE(S): Noevir Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002053431	A	20020219	JP 2000-240551	20000809 <--
PRIORITY APPLN. INFO.:			JP 2000-240551	20000809
OTHER SOURCE(S): MARPAT 136:189098				

AB The cosmetics contain polyhydric alcs., organic-modified clay minerals, and acyllactate salts. A composition containing benzyldimethylstearylammonium hectorite 2.0, Na isostearoyllactate 1.0, and polyethylene glycol 97.0 weight% showed good skin-moisturizing and -smoothing effects.

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:326216 CAPLUS
DOCUMENT NUMBER: 134:331356
TITLE: Cosmetic lotions containing heat-generating inorg. salts for massage
INVENTOR(S): Hanano, Akinori
PATENT ASSIGNEE(S): Noevir Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001122722	A	20010508	JP 1999-297693	19991020 <--
PRIORITY APPLN. INFO.:			JP 1999-297693	19991020

AB The lotions contain polyethylene glycol (average mol. weight ≤ 600), inorg. salts which generate heat upon hydration, and pigments. A lotion containing polyethylene glycol 75, dry powdered seawater 10, talc 10, and SiO₂ 5 parts showed good warming effect and redispersibility of particles.


L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:192024 CAPLUS

DOCUMENT NUMBER: 134:231863
 TITLE: Piperazines and TNF- α formation inhibitors and/or IL-10 formation enhancers containing them
 INVENTOR(S): Adachi, Kunitomo; Hanano, Atsushi; Hisadome, Tadao; Fukuda, Akiko
 PATENT ASSIGNEE(S): Welfide KK, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 54 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001072660	A	20010321	JP 1999-253914	19990908 <--
PRIORITY APPLN. INFO.:			JP 1999-253914	19990908
OTHER SOURCE(S):	MARPAT	134:231863		

GI



I

AB Piperazines I [Q = XY, heterocyclyl; X = (un)substituted amino, etc.; Y = single bond, alkylene; Z = alkylene, etc.; R1, R2 = halo, alkyl, amino, NO₂, OH; R3 = lower alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl] or their salts are useful for TNF- α formation inhibitors and/or IL-10 formation enhancers for treatment of autoimmune diseases. Lipopolysaccharide-induced TNF- α formation in mice was reduced to 10% (as compared to controls) by administration of N-[4-[3-(4-phenylpiperazin-1-yl)propyl]phenylmethyl]acetamide at 10 mg/kg p.o. Preparation procedures for the piperazines and formulation examples are given.

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:772789 CAPLUS
 DOCUMENT NUMBER: 132:14690
 TITLE: anticorrosive paint coating on magnesium alloys for injection moldings of improved quality and for preventing dust formation
 INVENTOR(S): Hanano, Akira
 PATENT ASSIGNEE(S): Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11335875	A	19991207	JP 1998-173761	19980519 <--
PRIORITY APPLN. INFO.:			JP 1998-173761	19980519

AB The coating is applied on the Mg alloy before the injection molding in

oder to prevent the surface oxydation and to prevent the dust formation causing explosive fire.

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1980:554797 CAPLUS
DOCUMENT NUMBER: 93:154797
ORIGINAL REFERENCE NO.: 93:24603a,24606a
TITLE: Quality of lime stones produced in Kumamoto, Japan, and the use in concrete production
AUTHOR(S): Hanano, Akihisa
CORPORATE SOURCE: Kumamoto-Ken Kogyo Shikenjo, Japan
SOURCE: Kenkyu Hokoku - Kumamoto-ken Kogyo Shikenjo (1979), Volume Date 1978 147-61
CODEN: KHKSDU
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB Local limestone was used as coarse aggregates for concrete manufacture The limestone had high d. and low water absorption, but high abrasion. Concretes made with the limestone had suitable strength, and the use of limestone as aggregates is practical.

L3 ANSWER 7 OF 9 MEDLINE on STN

ACCESSION NUMBER: 1979190728 MEDLINE
DOCUMENT NUMBER: PubMed ID: 446147
TITLE: Peripheral pulmonary embolization from central pulmonary aneurysm.
AUTHOR: Cole F H Jr; Hanano A A; Pate J W
SOURCE: Chest, (1979 Apr) Vol. 75, No. 4, pp. 517-8.
Journal code: 0231335. ISSN: 0012-3692.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 197908
ENTRY DATE: Entered STN: 15 Mar 1990
Last Updated on STN: 15 Mar 1990
Entered Medline: 16 Aug 1979
AB A 59-year-old man underwent successful repair of a pulmonary arterial aneurysm because of peripheral pulmonary embolization. These lesions are relatively rare; and, to our knowledge, peripheral embolization from such an aneurysm has not been previously reported.

L3 ANSWER 8 OF 9 MEDLINE on STN

ACCESSION NUMBER: 1964094954 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14137055
TITLE: A CASE DEVELOPED A SHOCK SYMPTOM WITH BSP INJECTION.
AUTHOR: YUNOMURA R; HANANO A
SOURCE: Naika. Internal medicine, (1964 Feb) Vol. 13, pp. 383-6.
Journal code: 0413541. ISSN: 0022-1961.
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Japanese
FILE SEGMENT: OLDMEDLINE; NONMEDLINE
ENTRY MONTH: 199612
ENTRY DATE: Entered STN: 16 Jul 1999
Last Updated on STN: 16 Jul 1999
Entered Medline: 1 Dec 1996

L3 ANSWER 9 OF 9 MEDLINE on STN

ACCESSION NUMBER: 1964094472 MEDLINE

DOCUMENT NUMBER: PubMed ID: 14136574
 TITLE: STATISTICAL OBSERVATIONS ON CEREBRAL APOPLEXY SEEN AT THE CLINIC FOR 2 YEARS AND 8 MONTHS; A PRELIMINARY REPORT.
 AUTHOR: TAMURA A; YUMURA R; HANANO A
 SOURCE: [Sogo rinsho] Clinic all-round, (1964 Feb) Vol. 13, pp. 337-42.
 Journal code: 20910550R. ISSN: 0371-1900.
 PUB. COUNTRY: Japan
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: Japanese
 FILE SEGMENT: OLDMEDLINE; NONMEDLINE
 ENTRY MONTH: 199612
 ENTRY DATE: Entered STN: 16 Jul 1999
 Last Updated on STN: 16 Jul 1999
 Entered Medline: 1 Dec 1996

=> s glycolic and polyethylene and glycol and peel and skin
 L4 5 GLYCOLIC AND POLYETHYLENE AND GLYCOL AND PEEL AND SKIN

=> d l4 ibib abs 1-4

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:138982 CAPLUS
 DOCUMENT NUMBER: 150:199360
 TITLE: Compositions and methods for dermally treating neuropathy with minoxidil
 INVENTOR(S): Sanjay, Sharma; Zhang, Jie; Warner, Kevin S.
 PATENT ASSIGNEE(S): Zars Pharma, Inc., USA
 SOURCE: PCT Int. Appl., 48pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017767	A2	20090205	WO 2008-US9222	20080730
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080019927	A1	20080124	US 2007-888905	20070801
PRIORITY APPLN. INFO.:			US 2007-888905	A 20070801
			US 2004-577536P	P 20040607
			US 2005-146917	A2 20050606
			US 2005-750519P	P 20051214
			US 2005-750637P	P 20051214
			US 2006-640135	A2 20061214
			US 2006-640139	A2 20061214

AB The present invention is drawn to adhesive solidifying formulations containing minoxidil that can be used for treating neuropathies including diabetic neuropathy. The formulation can include an amount of minoxidil, a solvent

vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the minoxidil at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. Thus, a solidifying formulation for treating diabetic neuropathy and the associated neuropathic pain was prepared containing minoxidil 5, polyvinyl alc. 22.2, propylene glycol 22.2, ethanol 4.4, 5M HCl solution 1.8, and water 44.4%, resp. A solidified peel formulation was formed when the composition obtained was spread on a silicone-coated polyester release liner and the solidified peel was stretchable by 5% in one direction without cracking or splitting.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:993749 CAPLUS
DOCUMENT NUMBER: 147:330433
TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling
PATENT ASSIGNEE(S): Tristrata, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228
WO 2007103687	A2	20070913	WO 2007-US62975	20070228
WO 2007103687	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1998788	A2	20081210	EP 2007-757636	20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-778128P P 20060301
WO 2007-US62975 W 20070228

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the

mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:670139 CAPLUS
DOCUMENT NUMBER: 147:79575
TITLE: Compositions comprising drugs, a solvent vehicle, and a solidifying agent for dermally treating pain
INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay
PATENT ASSIGNEE(S): Zars, Inc., USA
SOURCE: PCT Int. Appl., 84pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070679	A2	20070621	WO 2006-US47926	20061214
WO 2007070679	A3	20090108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006326018	A1	20070621	AU 2006-326018	20061214
CA 2633515	A1	20070621	CA 2006-2633515	20061214
AU 2006339350	A1	20070907	AU 2006-339350	20061214
CA 2633464	A1	20070907	CA 2006-2633464	20061214
EP 1959931	A2	20080827	EP 2006-848632	20061214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
EP 1968541	A2	20080917	EP 2006-849969	20061214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2008MN01481	A	20081010	IN 2008-MN1481	20080714
IN 2008MN01485	A	20081017	IN 2008-MN1485	20080714
CN 101370453	A	20090218	CN 2006-80052642	20080811
PRIORITY APPLN. INFO.:			US 2005-750519P	P 20051214
			US 2005-750637P	P 20051214
			US 2005-750683P	P 20051214
			US 2005-750521P	P 20051214
			WO 2006-US47926	W 20061214
			WO 2006-US48059	W 20061214

AB The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating pain, such as musculoskeletal pain, inflammation, joint pain, or neuropathic pain. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein the evaporation of at least some of the volatile solvent converts the formulation on the skin into a solidified layer and the non-volatile solvent system is capable of facilitating the topical delivery of the drug(s) at therapeutically effective rates over a sustained period of time. Using hairless mouse skin permeation expts., a formulation of ropivacaine, the non-volatile solvents glycerol and Tween 20 had low steady state flux values and would not be considered "flux-enabling", but mineral oil and isostearic acid are flux-enabling solvents and are good candidates for evaluation with solidifying agents and volatile solvents to design an acceptable peel formulation.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1282494 CAPLUS
DOCUMENT NUMBER: 144:40380
TITLE: Alcohol-based hand sanitizing composition
INVENTOR(S): Brown, James Steven
PATENT ASSIGNEE(S): James Steven Brown, USA
SOURCE: Brit. UK Pat. Appl., 53 pp.
CODEN: BAXXD
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2414666	A	20051207	GB 2004-12329	20040603
GB 2414666	B	20090107		
GB 2452189	A	20090225	GB 2008-21820	20040603
US 20050271595	A1	20051208	US 2005-102017	20050409
AU 2005327300	A1	20060817	AU 2005-327300	20050601
CA 2568888	A1	20060817	CA 2005-2568888	20050601
WO 2006085907	A2	20060817	WO 2005-US18992	20050601
WO 2006085907	A3	20061005		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1765260	A2	20070328	EP 2005-856772	20050601
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008508189	T	20080321	JP 2007-515471	20050601
PRIORITY APPLN. INFO.:			GB 2004-12329	A3 20040603
			US 2005-102017	A 20050409
			WO 2005-US18992	W 20050601

AB The invention provides a sanitizing composition in the form of a viscous liquid

or gel suitable for use as a handwashing composition comprising alc., water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin, e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colorings or UV markers. For example, a composition contained ethanol 62.0%, Carbopol ETD 2020 thickener 0.3%, diisopropanolamine 0.01%, disodium EDTA 0.01%, suspended particles Florasomes MXS Blue with fragrance and Fluorescent Brightener 236 0.5% and Florasomes MXS with triclosan 0.8%, and water to 100%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s glycolic and polyethylene and peel and skin
L5 9 GLYCOLIC AND POLYETHYLENE AND PEEL AND SKIN

=> d 15 ibib abs 1-9

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:138982 CAPLUS
DOCUMENT NUMBER: 150:199360
TITLE: Compositions and methods for dermally treating neuropathy with minoxidil
INVENTOR(S): Sanjay, Sharma; Zhang, Jie; Warner, Kevin S.
PATENT ASSIGNEE(S): Zars Pharma, Inc., USA
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017767	A2	20090205	WO 2008-US9222	20080730
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080019927	A1	20080124	US 2007-888905	20070801
PRIORITY APPLN. INFO.:			US 2007-888905	A 20070801
			US 2004-577536P	P 20040607
			US 2005-146917	A2 20050606
			US 2005-750519P	P 20051214
			US 2005-750637P	P 20051214
			US 2006-640135	A2 20061214
			US 2006-640139	A2 20061214

AB The present invention is drawn to adhesive solidifying formulations containing minoxidil that can be used for treating neuropathies including diabetic neuropathy. The formulation can include an amount of minoxidil, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a

non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the minoxidil at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. Thus, a solidifying formulation for treating diabetic neuropathy and the associated neuropathic pain was prepared containing minoxidil 5, polyvinyl alc. 22.2, propylene glycol 22.2, ethanol 4.4, 5M HCl solution 1.8, and water 44.4%, resp. A solidified peel formulation was formed when the composition obtained was spread on a silicone-coated polyester release liner and the solidified peel was stretchable by 5% in one direction without cracking or splitting.

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:993749 CAPLUS
DOCUMENT NUMBER: 147:330433
TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling
PATENT ASSIGNEE(S): Tristrata, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228
WO 2007103687	A2	20070913	WO 2007-US62975	20070228
WO 2007103687	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1998788	A2	20081210	EP 2007-757636	20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: US 2006-778128P P 20060301
WO 2007-US62975 W 20070228

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to

skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:670139 CAPLUS

DOCUMENT NUMBER: 147:79575

TITLE: Compositions comprising drugs, a solvent vehicle, and a solidifying agent for dermally treating pain

INVENTOR(S): Zhang, Jie; Warner, Kevin S.; Sharma, Sanjay

PATENT ASSIGNEE(S): Zars, Inc., USA

SOURCE: PCT Int. Appl., 84pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 19

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070679	A2	20070621	WO 2006-US47926	20061214
WO 2007070679	A3	20090108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006326018	A1	20070621	AU 2006-326018	20061214
CA 2633515	A1	20070621	CA 2006-2633515	20061214
AU 2006339350	A1	20070907	AU 2006-339350	20061214
CA 2633464	A1	20070907	CA 2006-2633464	20061214
EP 1959931	A2	20080827	EP 2006-848632	20061214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
EP 1968541	A2	20080917	EP 2006-849969	20061214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
IN 2008MN01481	A	20081010	IN 2008-MN1481	20080714
IN 2008MN01485	A	20081017	IN 2008-MN1485	20080714
CN 101370453	A	20090218	CN 2006-80052642	20080811
PRIORITY APPLN. INFO.:			US 2005-750519P	P 20051214
			US 2005-750637P	P 20051214
			US 2005-750683P	P 20051214
			US 2005-750521P	P 20051214
			WO 2006-US47926	W 20061214
			WO 2006-US48059	W 20061214

AB The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating pain, such as musculoskeletal pain,

inflammation, joint pain, or neuropathic pain. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein the evaporation of at least some of the volatile solvent converts the formulation on the skin into a solidified layer and the non-volatile solvent system is capable of facilitating the topical delivery of the drug(s) at therapeutically effective rates over a sustained period of time. Using hairless mouse skin permeation expts., a formulation of ropivacaine, the non-volatile solvents glycerol and Tween 20 had low steady state flux values and would not be considered "flux-enabling", but mineral oil and isostearic acid are flux-enabling solvents and are good candidates for evaluation with solidifying agents and volatile solvents to design an acceptable peel formulation.

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1282494 CAPLUS
DOCUMENT NUMBER: 144:40380
TITLE: Alcohol-based hand sanitizing composition
INVENTOR(S): Brown, James Steven
PATENT ASSIGNEE(S): James Steven Brown, USA
SOURCE: Brit. UK Pat. Appl., 53 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2414666	A	20051207	GB 2004-12329	20040603
GB 2414666	B	20090107		
GB 2452189	A	20090225	GB 2008-21820	20040603
US 20050271595	A1	20051208	US 2005-102017	20050409
AU 2005327300	A1	20060817	AU 2005-327300	20050601
CA 2568888	A1	20060817	CA 2005-2568888	20050601
WO 2006085907	A2	20060817	WO 2005-US18992	20050601
WO 2006085907	A3	20061005		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1765260	A2	20070328	EP 2005-856772	20050601
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008508189	T	20080321	JP 2007-515471	20050601
PRIORITY APPLN. INFO.:				
			GB 2004-12329	A3 20040603
			US 2005-102017	A 20050409
			WO 2005-US18992	W 20050601

AB The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwashing composition comprising alc., water and a thickener wherein the viscous liquid or gel has particles suspended

therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin, e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colorings or UV markers. For example, a composition contained ethanol 62.0%, Carbopol ETD 2020 thickener 0.3%, diisopropanolamine 0.01%, disodium EDTA 0.01%, suspended particles Florasomes MXS Blue with fragrance and Fluorescent Brightener 236 0.5% and Florasomes MXS with triclosan 0.8%, and water to 100%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:934139 CAPLUS

DOCUMENT NUMBER: 141:400499

TITLE: Cosmetic and pharmaceutical ion-pair delivery system based masks comprising biopolymer based films cross-linked with metal cations

INVENTOR(S): Gupta, Shyam K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20040219124	A1	20041104	US 2003-249701	20030501
US 20060198805	A1	20060907	US 2005-164709	20051202
PRIORITY APPLN. INFO.:			US 2003-249701	A2 20030501

AB The present invention discloses a novel ion-pair delivery system based mask compns. for face, hair, skin, and body applications. These compns. come off from the site of their application essentially in one piece with the appearance, for example, of a piece of sea-weed or a continuous film. These mask compns. are suitable for a variety of delivery system methods, such as peel-off mask, moisturizing mask, exfoliating mask, prosthetic mask, soaking mask, depilatory mask, rub-off mask, two-phase mask, two-compartment mask, heat-releasing mask, and such. These mask compns. are made from the biopolymer based films that are cross-linked with divalent or trivalent metal cations. During the crosslinking process, such divalent and trivalent metal cations may also act as release agents for other face, hair, skin, and body beneficial compns. in their enhanced bioavailable forms by an ion-pair activation mechanism.

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:681187 CAPLUS

DOCUMENT NUMBER: 141:194959

TITLE: Skin firming anti-aging cosmetic compositions

INVENTOR(S): Gupta, Shyam K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 US 20040161435 A1 20040819 US 2003-248753 20030214
 PRIORITY APPLN. INFO.: US 2003-248753 20030214
 AB Cosmetic mask compns. suitable for face, neck, chin or body applications
 are disclosed. These compns. synergistically combine at least 1
 skin beneficial cosmetic or pharmaceutical composition with at least
 one composition to promote excess fat reduction, cellulite control, or muscle
 toning benefits. The mask composition also contains at least one binder
 composition
 that binds with other beneficial ingredients by electrostatic, atomic, or
 ionic charges to synergistically enhance their topical site-specific
 benefits. These mask compns. are suitable for a variety of delivery
 system methods that include, e.g., peel-off mask, leave-in mask,
 moisturizing mask, and exfoliating mask. Thua, a facial mask composition
 contained chitosan 5.0, lactic acid 5.0, glycerin 18.0, water 65.8,
 hydroxycitric acid 5.0, niacinamide 0.5, glutathione, and preservatives
 0.5%.

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:681176 CAPLUS
 DOCUMENT NUMBER: 141:195302
 TITLE: Skin peeling composition containing
 salicylic acid derivatives
 INVENTOR(S): Hansenne, Isabelle; Fares, Hani; Cornell, Marc;
 Foltis, Sidney P.
 PATENT ASSIGNEE(S): L'Oreal S.A., Fr.
 SOURCE: U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040161392	A1	20040819	US 2003-367952	20030219
WO 2004073605	A2	20040902	WO 2004-US1527	20040120
WO 2004073605	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601339	A2	20051207	EP 2004-703693	20040120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007227	A	20060131	BR 2004-7227	20040120
JP 2006518340	T	20060810	JP 2005-518836	20040120
US 20080146529	A1	20080619	US 2008-10897	20080131
PRIORITY APPLN. INFO.:			US 2003-367952	A 20030219
			WO 2004-US1527	W 20040120

OTHER SOURCE(S): MARPAT 141:195302

AB The present invention relates to methods of peeling skin using
 certain salicylic acid derivs., to chemical skin peel
 compns. containing these certain salicylic acid derivs. in a carrier,
 preferably a dermatol. acceptable carrier, to methods of making these
 compns., and methods of applying this certain compound and/or composition to
 skin to be peeled. For example, a skin-peeling composition
 contained 35% 5-n-octanoylsalicylic acid mixed with a blend of

ethanol/propylene glycol.

L5 ANSWER 8 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2006740824 MEDLINE
DOCUMENT NUMBER: PubMed ID: 17179618
TITLE: Preparation and evaluation of cosmetic patches containing
lactic and glycolic acids.
AUTHOR: Mahdavi H; Kermani Z; Faghihi G; Asilian A; Hamishehkar H;
Jamshidi A
CORPORATE SOURCE: Department of Novel Drug Delivery Systems, Science Faculty,
Iran Polymer and Petrochemical Institute, Tehran, Iran..
H.Mahdavi@ippi.ac.ir
SOURCE: Indian journal of dermatology, venereology and leprology,
(2006 Nov-Dec) Vol. 72, No. 6, pp. 432-6.
Journal code: 7701852. E-ISSN: 0973-3922.
PUB. COUNTRY: India
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200701
ENTRY DATE: Entered STN: 21 Dec 2006
Last Updated on STN: 27 Jan 2007
Entered Medline: 26 Jan 2007

AB BACKGROUND: Alpha-hydroxy acids such as glycolic acid (GA) and
lactic acid (LA), are used in cosmetic patches. The important fact in
cosmetic patches is its suitable adhesion and peel properties.
AIM: The objective of this study was to prepare LA- and GA-containing
cosmetic patches and evaluate in-vitro/in-vivo correlation of adhesion
properties. METHODS: Pressure-sensitive adhesives with different
concentrations of GA and LA were cast on a polyethylene
terephthalate film. The patches were evaluated for peel
adhesive strength. On the basis of in vitro adhesion properties the
patches were selected for wear performance tests and skin
irritation potential. RESULTS: The adhesion properties (adhesion to steel
plate and skin) and cohesive strength tests indicated the
substantial influence of GA and LA concentrations. Based on in vitro
adhesion studies the patches containing 3% (w/w) GA were selected for in
vivo studies. In vivo studies show that a formulation containing 3% GA
displays good adhesion on the skin, but it leaves little
residues on the skin. Skin Irritation studies on
healthy human volunteers showed negligible erythema at the site of
application after 48 h. CONCLUSION: The noninvasive patch test model was
found useful for detecting irritant skin reactions to the
cosmetic patch containing GA. Our results demonstrated a strong
correlation between the adhesion to steel plate and adhesion to
skin. But a weak correlation between the degree of adhesive
residue on the skin in in vitro and in vivo tests was observed
for the formulation containing 3% (w/w) GA.

L5 ANSWER 9 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2003610331 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14692936
TITLE: The treatment of hypopigmentation after skin
resurfacing.
AUTHOR: Fulton James E Jr; Rahimi A David; Mansoor Sohail; Helton
Peter; Shitabata Paul
CORPORATE SOURCE: Fulton Skin Institute, Tustin, California, USA.
SOURCE: Dermatologic surgery : official publication for American
Society for Dermatologic Surgery [et al.], (2004 Jan) Vol.
30, No. 1, pp. 95-101.
Journal code: 9504371. ISSN: 1076-0512.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 25 Dec 2003
Last Updated on STN: 12 Mar 2004
Entered Medline: 11 Mar 2004

AB BACKGROUND: Hypopigmentation has plagued all methods of skin resurfacing. Whether the physician uses chemical peels, dermabrasion or laser resurfacing hypopigmentation can develop. OBJECTIVE: To examine the pathogenesis and treatment of hypopigmentation after resurfacing. METHODS: Areas of hypopigmentation after skin resurfacing were blended in with laser-assisted chemabrasion (LACA). The process begins with preconditioning of the skin with vitamin A/glycolic skin conditioning lotions. Then the area is resurfaced with the LACA. This resurfacing usually requires three to four freeze-sand cycles to remove the areas of hypopigmentation associated with dermal fibrosis. The resurfaced skin is then occluded with a combination of polyethylene/silicone sheeting during the acute phase of wound healing. Ultraviolet photography and histologic examination were used to demonstrate the improvement in dermal fibrosis and hypopigmentation. RESULTS: The LACA improved areas of hypopigmentation in the 22 cases studied. Under occlusive wound dressings, the melanocytes migrated into the areas of hypopigmentation, and the wounds healed without extensive fibrosis. This produced a blending of skin color. CONCLUSION: It is possible with skin preconditioning, LACA, and occlusive wound healing to provide for a wound healing environment that blends in areas of hypopigmentation that have developed after previous skin resurfacing.

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/Caplus patent records provide insights into related prior

```

art
NEWS 11 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 12 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 13 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 16 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
formats
NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text
applications and grants
NEWS 19 MAR 11 ESBIOBASE reloaded and enhanced
NEWS 20 MAR 20 CAS databases on STN enhanced with new super role
for nanomaterial substances
NEWS 21 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China
NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced
NEWS 23 APR 03 CAS coverage of exemplified prophetic substances
enhanced
NEWS 24 APR 07 STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:12:46 ON 15 APR 2009

```

=> file caplus medline
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                              ENTRY      SESSION
FULL ESTIMATED COST          0.22      0.22

```

FILE 'CAPLUS' ENTERED AT 12:12:59 ON 15 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:12:59 ON 15 APR 2009

```

=> peg 45m
PEG IS NOT A RECOGNIZED COMMAND

```

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s peg 45m

L1 2 PEG 45M

=> d l1 ibib abs 1-2

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:975589 CAPLUS

DOCUMENT NUMBER: 143:253460

TITLE: Hair treatment compositions containing surfactants and polyethylene glycol

INVENTOR(S): Cajan, Christine; Lehn, Jutta

PATENT ASSIGNEE(S): KPSS-KAO Professional Salon Services GmbH, Germany

SOURCE: Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1570833	A1	20050907	EP 2004-5224	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 20050196372	A1	20050908	US 2005-70173	20050302
PRIORITY APPLN. INFO.:			EP 2004-5224	A 20040305

OTHER SOURCE(S): MARPAT 143:253460

AB The present invention concerns a hair treatment composition in the form of an emulsion, preferably of a microemulsion, which improves hair quality in terms of softness, shine and touch feeling. Emulsion type of hair treatment composition is characterized in that it comprises in a cosmetically acceptable aqueous medium surfactants as emulsifiers, natural and/or mineral oil, silicone oil, and at least one polyethylene glycol with a mol. weight of >10,000. Thus, a formulation comprised Dimethicone 2.00, mineral oil 15.00, PEG-7 glyceryl cocoate 10.00, and Ceteareth-20 20.00 in Phase A, PEG-45M 0.40, DMDM hydantoin 0.20, propylene glycol 5.00, glycerin 15.00, PVP 2.00 and water qs to 100% in Phase B, and 0.30% perfume in phase C.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:89458 CAPLUS

DOCUMENT NUMBER: 142:182927

TITLE: Surfactant-free shaving composition

INVENTOR(S): Heike, Kerstin; Treu, Jens; Post, Katharina; Wolter, Kathrin

PATENT ASSIGNEE(S): Beiersdorf A.-G., Germany

SOURCE: Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1502581	A1	20050202	EP 2004-102782	20040617

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 DE 10336044 A1 20050217 DE 2003-10336044 20030801
 US 20050036975 A1 20050217 US 2004-910202 20040802
 PRIORITY APPLN. INFO.: DE 2003-10336044 A 20030801
 AB The invention concerns shaving compns. for elec. shaving that contain a
 lipid and emulsifiers or does not contain emulsifiers or does not contain
 lipids and emulsifiers but contains crosslinked polyacrylates, glycerin,
 Xanthan gum and water; the compns. are free of surfactants, especially
 sarcosinates and have viscosities of 500-5000 mPa at room temperature Further
 ingredients are polyethylene glycol, hydrogenated-ethoxylated castor oil,
 cellulose derivs.; and for lipid-containing preps. ethylhexyl cocoate or
 other carboxylic acid esters are used. Thus a shaving emulsion contained
 (weight/weight%): Acrylates/C10-30 alkyl acrylate crosspolymer 0.5000;
 ethylhexyl cocoate 1.0000; biosaccharide gum 3.0000; isohexadecane 4.0000;
 PEG-45M 0.5000; sodium hydroxide 0.1000; triceteareth-4
 phosphate 1.5000; Xanthan gum 0.2000; fragrance 0.0500; water to 100.
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
 Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
 minutes
 NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
 (CS) field
 NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for
 U.S. patents
 NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
 CAS REGISTRY
 NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
 thesaurus
 NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
 Taiwanese Content Expanded
 NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
 translated claims for Chinese Applications and
 Utility Models
 NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS,
 USPATFULL, and USPAT2 in the month of November.

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
 AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:07:41 ON 28 OCT 2009

=> file caplus medline biosis embase

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'CAPLUS' ENTERED AT 11:08:01 ON 28 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:08:01 ON 28 OCT 2009

FILE 'BIOSIS' ENTERED AT 11:08:01 ON 28 OCT 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:08:01 ON 28 OCT 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> s (polyvinyl (s) alcohol) and glycolic and (skin or peel or exfoliat? or topical)

L1 104 (POLYVINYL (S) ALCOHOL) AND GLYCOLIC AND (SKIN OR PEEL OR EXFOLI
AT? OR TOPICAL)

=> s l1 not py>2003

L2 22 L1 NOT PY>2003

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 22 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 ibib abs 1-22

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:610222 CAPLUS

DOCUMENT NUMBER: 139:169003

TITLE: Cosmetic patch comprising a pressure sensitive
adhesive and a polymer

INVENTOR(S): Rolf, David; Buseman, Teri; Cooke, Dede

PATENT ASSIGNEE(S): Lectec Corporation, USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

WO 2003063817 A1 20030807 WO 2003-US2425 20030128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030152610 A1 20030814 US 2002-60060 20020128
PRIORITY APPLN. INFO.: US 2002-60060 A 20020128

AB An adhesive patch including a flexible backing having a front side and a back side and a cosmetic formulation positioned on and/or in at least a portion of the front side of the backing is provided. The cosmetic formulation includes a cosmetic agent, a solvent, a skin absorption enhancer, and at least one of a pressure sensitive adhesive and a polymer. For example, an adhesive patch contained polyacrylamide 13.0%, glycerin 53.5%, water 19.0%, vitamin A palmitate 0.25%, grape seed oil 0.5%, fragrance 0.25%, ammonium lactate 1.0%, propylene glycol 4.0%, diethylene glycol Et ether 5.0%, emulsion adhesive 3.0%, and preservative 0.5%.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:58810 CAPLUS

DOCUMENT NUMBER: 138:83428

TITLE: Tacrolimus formulations for the treatment of ocular disease

INVENTOR(S): Peyman, Gholam A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U.S. Pat. Appl. 2002 13,340.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030018044	A1	20030123	US 2002-247220	20020919
US 20020013340	A1	20020131	US 2000-507076	20000218
US 6489335	B2	20021203		

PRIORITY APPLN. INFO.: US 2000-507076 A2 20000218

AB A formulation to treat ocular disease, e.g. dry eye disease, as well as other diseases, is disclosed. Tacrolimus is administered intraocularly, e.g. topically or by injection. For topical administration, an amount of about 1 ng to 10 µg may be formulated in an aqueous based cream that may be applied at bedtime or throughout the day. For injection, a dose of about 20-1000 µg/mL is used. Tacrolimus may also be administered in milligram quantities as a surgical implant contained in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:170598 CAPLUS
DOCUMENT NUMBER: 140:344990
TITLE: Hydrocolloidal dressing coating
INVENTOR(S): Kirilenko, Yu. K.; Postnov, S. E.; Reshetov, I. V.;
Yudanova, T. N.
PATENT ASSIGNEE(S): Russia
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2219955	C2	20031227	RU 2001-126855	20011004
PRIORITY APPLN. INFO.:			RU 2001-126855	20011004

AB The invention relates to hydrocolloidal application coatings based on chitosan and also containing polyvinyl alc., organic acid, glutaric aldehyde, ethanol, and water, which is designed for use in treatment process to speed up epithelization of various wounds and to localize them on the body, as an agent preventing formation of hypertrophic and keloid cicatrices, for improving trophism of skin and mucosa, and which can likewise be utilized in cases of hyperkeratosis and age-caused skin pathol. The treatment process proceeds by compression hydrating action and transportation of biol. active prepsns.

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:477439 CAPLUS
DOCUMENT NUMBER: 146:427824
TITLE: Formulation of filmogenic action for topical
use containing tretinoin, glycolic acid and
clindamycin
INVENTOR(S): Crimi, Rocco; Cozzi, Raniero
PATENT ASSIGNEE(S): Laboratori Farmaceutici Krymi S.r.l., Italy
SOURCE: Ital. Appl., 13pp.
CODEN: ITXXCZ
DOCUMENT TYPE: Patent
LANGUAGE: Italian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IT 2003RM0081	A1	20030526	IT 2003-RM81	20030225
PRIORITY APPLN. INFO.:			IT 2003-RM81	20030225

AB An invention describing a formulation for topical use containing tretinoin, glycolic acid, polyvinyl alc. and clindamycin. The formulation is characterized by an innovative synergistic effect between the active components and by a preparation method with a novel solubilization of tretinoin. The formulation may be prepared in the form of gel, cream, lotion, mousse, spray or mask. The active principles are contained in the following range proportions: tretinoin (0.01-0.2%), glycolic acid (1-20%), clindamycin phosphate or hydrochloride (0.1-2.5%), and polyvinyl alc. (0.1-10%). The acidity of the formulation ranges between pH 2.5 to pH 6.5. The solubilization of tretinoin is obtained by the following process: a precise amount of tretinoin is maintained under a nitrogen current; an exact amount of cocoglyceryl 70E is placed in a sep. container, stirred and heated; as soon as the temperature reaches 30°C it is allowed to stabilized for a few minutes and afterwards it is mixed with tretinoin

rapidly. The mixture is stirred for 5 min until the solubilization is completed. Then the temperature is reduced rapidly to 25°C, with constant agitation. The formulation may be used in the treatment of acne and psoriasis.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:477440 CAPLUS
DOCUMENT NUMBER: 146:427825
TITLE: Formulation of filmogenic action for topical use containing tretinoin, glycolic acid and polyvinyl alcohol
INVENTOR(S): Crimi, Rocco; Cozzi, Raniero
PATENT ASSIGNEE(S): Laboratori Farmaceutici Krymi S.r.l., Italy
SOURCE: Ital. Appl., 11pp.
CODEN: ITXXCZ
DOCUMENT TYPE: Patent
LANGUAGE: Italian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IT 2003RM0080	A1	20030526	IT 2003-RM80	20030225
PRIORITY APPLN. INFO.:			IT 2003-RM80	20030225

AB An invention describing a formulation for topical use containing tretinoin, glycolic acid and polyvinyl alc.
The formulation is characterized by an innovative synergistic effect between the active components and by a preparation method with a novel solubilization of tretinoin. The formulation may be prepared in the form of gel, cream, lotion, mousse, spray or mask. The active principles are contained in the following range proportions: tretinoin (0.01-0.2%), glycolic acid (1-20%), polyvinyl alc. (0.1-10%). The acidity of the formulation ranges between pH 2.5 to pH 6.5. The solubilization of tretinoin is obtained by the following process: a precise amount of tretinoin is maintained under a nitrogen current; an exact amount of cocoglyceryl 7 is placed in a sep. container, stirred and heated; as soon as the temperature reaches 30°C it is allowed to stabilize for a few minutes and afterwards it is mixed with tretinoin rapidly. The mixture is stirred for 5 min until the solubilization is completed. Then the temperature is reduced rapidly to 25°C, with constant agitation.

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:575558 CAPLUS
DOCUMENT NUMBER: 137:129910
TITLE: Cosmetic and pharmaceutical preparations containing a combination of acid protease enzymes and acidic buffers
INVENTOR(S): Bishop, Michael; Gillis, Glen; Norton, Scott J.
PATENT ASSIGNEE(S): Actim Organics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 354,687.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020102285	A1	20020801	US 2002-59790	20020129
US 6656701	B2	20031202		

US 6569437 B1 20030527 US 1999-354687 19990716
 PRIORITY APPLN. INFO.: US 1999-354687 A2 19990716
 US 1996-664056 A3 19960613

AB Novel compns. comprising one or more of an acid protease and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient, useful for treating or preventing abnormal biol. conditions, diseases or disorders, and/or for improving the texture or appearance of the skin, and/or for enhancing epidermal exfoliation and/or for enhancing epidermal cell renewal and to methods for the use of the compns. The acid protease comprises one or more proteolytic enzymes which exhibit proteolytic activity at pH values below that of the surface of the skin, i.e., approx. pH 5.5. The acidic buffer comprises at least one acidic buffering component that can reversibly disassoc. hydrogen ions and has buffering capacity at pH values below that of the surface of the skin, i.e., approx. pH 5.5. or mixts. thereof with a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient. The buffer is capable of reducing the pH of the surface of the skin to less than pH 5.5 and is susceptible to neutralization by normal epidermal processes. Such types of abnormal biol. conditions, diseases or disorders include skin atrophy, i.e., the thinning and/or general degradation of the dermis often characterized by a decrease in collagen and/or elastin as well as decreased number, size and doubling potential of fibroblast cells, and other maladies including, but are not limited to dry skin, severe dry skin, dandruff, acne, keratosis, psoriasis, eczema, skin flakiness, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, hyperkeratotic skin, inflammatory dermatoses, age-related skin changes and skin in need of cleansers. A wash contained aspartic acid 1.5, deionized water 82.50, methylparaen 0.20, PEG-75 1.50, disodium EDTA 0.05, allantoin 0.25, glycereth-26 1.00, ethoxydiglycol 4.00, propylene glycol 4.00, and AFP-2000 5.00%.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:327828 CAPLUS

DOCUMENT NUMBER: 136:345791

TITLE: Acidic aqueous chlorite teat dip with improved emollient providing shelf life, sanitizing capacity and tissue protection

INVENTOR(S): Richter, Francis L.; Paquette, Cathy M.; Staub, Richard K.; Vegoe, Donald R.

PATENT ASSIGNEE(S): Ecolab Inc., USA

SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 938,653.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6379685	B1	20020430	US 1998-159729	19980924
US 6436444	B1	20020820	US 1997-938653	19970926
EP 906724	A1	19990407	EP 1998-303896	19980518
EP 906724	B1	20021009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 225606	T	20021015	AT 1998-303896	19980518
ZA 9807953	A	20000322	ZA 1998-7953	19980901

HK 1019036 A1 20030417 HK 1999-104118 19990922
PRIORITY APPLN. INFO.: US 1997-938653 A2 19970926

AB The mastitis control teat dip composition that can effectively reduce microbial populations on contact with a teat surface for an extended period of time comprises an acidulant part and a chlorite part. An aqueous acidulant part contains 0.1-15% of an antimicrobial weak acid or salt thereof, 0.1-15% of a weak organic or inorg. acid or salts thereof, 0.01-10% of a pseudoplastic thickener, 0.1-10% of lanolin or a lanolin derivative, and 0.1-15% of a polyhydroxy emollient; a chlorite part, substantially free of an organic component, consists of an alkali metal chlorite salt, e.g., sodium chlorite. The composition provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheol., a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compns. of the invention are made by combining an aqueous thickened liquid composition containing the organic components which

can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material containing an emollient package and can be immediately contacted with the target animals. For example, a 200 g batch of the following exptl. base formula and a 1 kg batch of the chlorite activator part was prepared Base formula (Part 1) (pH = 2.6) contained (by weight) glycerin (96%) 5.00%, isopropanol (99%) 2.00%, decanoic acid 1.50%, lactic acid (88%) 2.95%, xanthan gum 0.30%, water 60.93%, potassium benzoate 0.20%, KOH (40%) 0.12%, octanesulfonate 17.00%, and Elvanol Premix (10%) 10.00%. Activator chlorite formula (Part 2) (pH = 12.3) contained water 50.00% and sodium chlorite (25%) 50.00%. The mixed product made with 100 g of the Base Part 1 formula combined with 2.75 g of the activator Part 2 chlorite formula and the material was buffered to pH 2.9.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:39555 CAPLUS
DOCUMENT NUMBER: 136:107223
TITLE: Cleansing articles for skin and/or hair
INVENTOR(S): Albacarys, Lourdes Dessus; Mcatee, David Michael; Deckner, George Endel
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 65,991, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6338855	B1	20020115	US 1999-296334	19990422
PRIORITY APPLN. INFO.:			US 1996-738145	B2 19961025
			US 1996-738668	B1 19961025
			US 1997-974033	B2 19971119
			US 1998-65991	B2 19980424
			US 1998-83015P	P 19980424

AB The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair and

delivering skin care actives onto the skin or hair.

These articles are used by the consumer by wetting the dry article with water and generating lather by subjecting the wetted article to mech. forces, e.g., rubbing. The article comprises a water insol. substrate, a lathering surfactant, and a skin care active component.

Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component. The following ingredients containing PEG 0.5 and water qs to 100%. To the above mixture was added disodium EDTA 0.10, sodium lauroyl sarcosinate 3.33, cocamidopropyl betaine 3.33, decyl polyglucoside 3.33, methylparaben 0.25, phenoxyethanol 0.3, and benzyl alc. 0.3%. The following components water 2.0, butylene glycol 2.0, and propylparaben 0.15% were added to the above surfactant mixture. A skin-care active composition containing sucrose esters with cotton fatty acids 48.00, sucrose ester with behenic acid 12.00, petrolatum 10.00, tribehenin 5.00, and C10-30 cholesterol/lanosterol esters 18.00% and was added to the surfactant mixture.

OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:63453 CAPLUS

DOCUMENT NUMBER: 136:123645

TITLE: Topical pharmaceutical patch compositions containing nonsteroidal antiinflammatory agents

INVENTOR(S): Seitai, Yang Poy; Cho, Seimin

PATENT ASSIGNEE(S): Sang-A Pharmaceutical Co., Ltd., S. Korea

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002020274	A	20020123	JP 2000-175244	20000612
PRIORITY APPLN. INFO.:			JP 2000-175244	20000612

AB The invention relates to a topical pharmaceutical patch composition containing a nonsteroidal antiinflammatory agent as an active ingredient, having excellent drug-releasing, transdermal absorption, and skin adhesive properties without causing skin irritation, wherein the composition contains nonsteroidal antiinflammatory agent 0.01-2, alkyl pyrrolidone 0.5-10, hydrophilic polyether 1-15, hydrophilic nonionic surfactant 0.01-5, carboxyl group-containing water-soluble polymer or its salt 2-15, water-soluble vinyl polymer 0.1-10, water-insol. polyvalent metal salt 0.01-10, polyalc. 5-50 %, organic hydroxyacid, and water. A plaster-type patch was prepared from ketoprofen 0.3, polysorbate 80 0.5, Me pyrrolidone 3, polyethylene glycol 10, sodium CM-cellulose 4, sodium polyacrylate 6, vinylpyrrolidone-vinyl acetate copolymer 4, dried aluminum hydroxide gel 0.2, Me paraben 0.1, EDTA-2Na 0.5, tartaric acid 2.2, glycerin 28, and water q.s. to 100 %.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:106997 CAPLUS

DOCUMENT NUMBER: 138:124034

TITLE: Use of oxygen-absorbing substances in the fabrication of flexible tubes

INVENTOR(S): Jupin, Alain

PATENT ASSIGNEE(S): Cebal S.A., Fr.
 SOURCE: Fr. Demande, 11 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2825689	A1	20021213	FR 2001-7526	20010608
FR 2825689	B1	20030801		
AU 2002317223	A1	20021223	AU 2002-317223	20020606
PRIORITY APPLN. INFO.:			FR 2001-7526	A 20010608
			WO 2002-FR1923	W 20020606

AB Sealants for use in the manufacture of Al alloy tubular packaging for oxidation-sensitive liqs. and pastes such as skin conditioners contain O-absorbers optionally encapsulated in water- or oil-soluble polymers.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:868220 CAPLUS

DOCUMENT NUMBER: 136:11149

TITLE: Medicinal compositions containing thiophene derivatives and biodegradable polymers, and manufacture thereof

INVENTOR(S): Hoshino, Tetsuo; Kawase, Masahiro; Ohta, Atsushi; Yasuma, Tsuneo; Kamei, Shigeru

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089521	A1	20011129	WO 2001-JP4298	20010523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2002047184	A	20020212	JP 2001-153565	20010523
PRIORITY APPLN. INFO.:			JP 2000-155973	A 20000523

OTHER SOURCE(S): MARPAT 136:11149

GI



AB Disclosed are medicinal compns. allowing a physiol. active substance (drug), which has an effect of promoting osteogenesis and chondrogenesis, to stable act over a long time at an affected part. These medicinal compns. contain compds. represented I [R1 = hydrocarbon, heterocycle group, sulfinyl, sulfonyl, hydroxy, thiol, amino; R2 = cyano, formyl, thioformyl, Z1-Z2 (Z1 = Co, CS, SO, SO2; Z2 = hydrocarbon, heterocycle group, hydroxy, amino); Aa = 5-7 membered ring; and R = H, halogen, cyano, amino, acyl, hydrocarbon, heterocycle group] or salts thereof together with a biodegradable polymer compound A compound 4,5-dihydro-1-methyl-8-phenoxy-1H-thieno[3,4-g]indazole-6-carboxamide was prepared A dichloromethane solution of the obtained compound was combined with lactic acid-glycolic acid copolymer and polyvinyl alc. (EG-40) to obtain microcapsules.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 22 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000409435 EMBASE
 TITLE: Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method.
 AUTHOR: Yang, Y.-Y. (correspondence); Chung, T.-S.; Ping Ng, N.
 CORPORATE SOURCE: Institute Materials Res./Engineering, No. 3 Research Link, National University of Singapore, 117602 Singapore, Singapore. yy-yang@imre.org.sg
 SOURCE: Biomaterials, (Feb 2001) Vol. 22, No. 3, pp. 231-241.
 Refs: 36
 ISSN: 0142-9612 CODEN: BIMADU
 PUBLISHER IDENT.: S 0142-9612(00)00178-2
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
 030 Clinical and Experimental Pharmacology
 037 Drug Literature Index
 039 Pharmacy
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 13 Dec 2000
 Last Updated on STN: 13 Dec 2000

AB The surface and internal morphology, drug distribution and release kinetics at 22°C of polyesters such as PCL (polycaprolactone) and PLGA (poly(DL-lactic-co-glycolic acid)) 65:35 microspheres containing BSA (bovine serum albumin) have been investigated in order to understand the relationship amongst morphology, drug distribution and in vitro release profiles and to develop controlled release devices for marine fishes in tropical area. CLSM (confocal laser scanning microscope)

micrographs reveal that the polyvinylalcohol (PVA as an emulsifier) concentration in the external water phase strongly influences drug distribution within microspheres and release profiles. The presence of PVA in the internal water phase enhances the stabilization of inner water droplets against coalescence. This results in a more uniform drug distribution and a slower BSA release. Different oil-phase volumes and polymer concentrations yield different solvent exchange and precipitation mechanisms, which lead to different morphologies. A low oil-phase volume yields microspheres with a porous matrix and defective skin surface, which gives a high initial BSA burst as well as a fast release profile. Microspheres fabricated from a low polymer concentration have less defective skin surface, but with a less tortuous inner matrix which results in a more rapid BSA release. A higher BSA loading yields a larger concentration gradient between the emulsion droplet and the continuous water phase as well as between the microspheres and the in vitro medium. The former results in a lower encapsulation efficiency, whereas the latter yields a faster initial burst and a more rapid release profile. High stirring speed can reduce microsphere size, but decreases the yield of microspheres. Copyright (C) 2000 Elsevier Science B.V.

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:790140 CAPLUS

DOCUMENT NUMBER: 133:339981

TITLE: Lotionized tissue products containing a pH balance compound for the skin

INVENTOR(S): Luu, Phuong V.; Oriaran, Philips T.; White, David W.; Awofeso, Anthony O.; Schroeder, Gary L.; Fredericks, Richard E.

PATENT ASSIGNEE(S): Fort James Corporation, USA

SOURCE: Eur. Pat. Appl., 7 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1050297	A2	20001108	EP 2000-109038	20000427
EP 1050297	A3	20001115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6352700	B1	20020305	US 1999-303660	19990503
CA 2306594	A1	20001103	CA 2000-2306594	20000425

PRIORITY APPLN. INFO.: US 1999-303660 A 19990503

AB A substrate treated with a lotion including a skin pH balancing compound and a base lotion. The pH balancing compound is preferably an organic acid, such as an alpha-hydroxy acid, an alpha-dihydroxy acid, or a beta-hydroxy acid, a combination of an organic acid and a salt of an organic acid, or a buffer combination, such as combinations of citric acid and disodium phosphate, or disodium citrate and sodium hydroxide. The preferred lotion has the effect of maintaining the skin acid mantle while making the treated substrate, preferably tissue, towel or napkin, optionally wet-strengthened, wipe or nonwoven material, feel smooth, lubricious and nongreasy. The skin care benefits of the lotionized substrate are expressed whether the product is used dry or prewetted with water. A lotion containing C12-15 alkyl benzoate (Finsolv TN) 35, cetearyl alc. (Crodacol CS 50) 63, and glycolic acid 2 % was formulated, and applied on one-ply tissue paper to obtain a lotionized tissue product.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:155353 CAPLUS

DOCUMENT NUMBER: 133:79151

TITLE: Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method

AUTHOR(S): Yang, Y.-Y. Y.-Y.; Chung, T.-S.; Bai, X.-L.; Chan, W.-K.

CORPORATE SOURCE: 3 Research Link, Institute of Materials Research & Engineering, National University of Singapore, Singapore, Singapore

SOURCE: Chemical Engineering Science (2000), 55(12), 2223-2236
CODEN: CESCAC; ISSN: 0009-2509

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have investigated the key parameters to fabricate PDLLA (Poly(dl-lactic acid)), PDLLGA (Poly(dl-lactic-co-glycolic acid)) 65:35 and blends of PDLLGA 65:35 and PEG (Poly(ethylene glycol)) microspheres containing bovine serum albumin (BSA) as a model protein using the double-emulsion (water-in-oil-in-water) solvent extraction/evaporation method. The release profiles

of microspheres were investigated at 22°C in order to develop controlled release devices for marine fishes in tropical area. Various factors that influence the size of microspheres, encapsulation efficiency, initial release, morphol. and release profiles of microspheres, and BSA distribution within microspheres have been investigated. These factors include preparation temperature, solvent removal rate, volume ratio of oil

phase to

internal water phase, and polymer concentration Microspheres fabricated at a low

volume ratio of oil phase to internal water phase and a low polymer concentration

tend to have a large surface area, a low bulk d., resulting in a high initial burst and a fast release of BSA. Fabrication temperature heavily affects solvent extraction/evaporation and mechanism of phase-inversion. The microspheres fabricated at 4 and 38°C yield the highest encapsulation efficiency (52.0-48.0%) and lowest initial BSA release (18.8-20.0%), while microspheres produced at 22°C have the lowest encapsulation efficiency and highest initial burst. This interesting phenomenon is due to the fact that different phase-inversion paths occur when preparation temperature varies. Nucleation growth and spinodal

decomposition

dominate the skin formation at low preparation temps., while evaporation-driven skin formation takes place at high preparation temps. The relationship between the release profile and the rate of continuous water-phase addition is extremely complicated. Slow demixing dominates the interface skin formation at low continuous water-phase addition rates and results in fine porous skin structure, while rapid demixing dominates at high continuous water-phase addition rates and also leads to microspheres with a porous skin. Thus both have high initial bursts and fast release rates. A continuous water-phase addition of 3 mL/min may yield the microspheres having a low initial burst and a slow release rate.

OS.CITING REF COUNT: 70 THERE ARE 70 CAPLUS RECORDS THAT CITE THIS RECORD (71 CITINGS)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:487205 CAPLUS
DOCUMENT NUMBER: 131:120626
TITLE: Skin care cosmetic method and system
INVENTOR(S): Habif, Stephan Samuel; Knaggs, Helen Elizabeth;
Becker, William Dwight; Brown, Martha Ann; Miner,
Philip Edward
PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever N.V.; Hindustan Lever
Limited
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937281	A1	19990729	WO 1999-EP335	19990121
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9924230	A	19990809	AU 1999-24230	19990121
PRIORITY APPLN. INFO.:			US 1998-72249P	P 19980123
			WO 1999-EP335	W 19990121

AB Disclosed are a cosmetic system and method for delivering a compound having an octanol/water coefficient log P in the range of from -2 to 6 to the skin. A cosmetic kit comprises (1) a flexible substrate sheet impregnated with an adhesive composition; (2) a skin-care composition; and (3) an instruction for a sequential application to the skin of the sheet followed by the composition. Also disclosed is a cosmetic method and system for protecting the skin from UV ray damage, after the skin has been stripped with an adhesive composition. A flexible sheet contained Gantrez ES-225 87.8, propylene carbonate 3.98, silica 0.76, titania 0.6, Abil-8852 0.25, Glydant plus 0.006, and water 6.624 % on a nonwoven fiber blend of rayon and polypropylene. A skin-care composition containing ascorbic acid, retinol, glycolic acid, etc. was also formulated to be used after removing the sheet.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:273081 CAPLUS
DOCUMENT NUMBER: 140:258618
TITLE: Cosmetic facial mask composition
INVENTOR(S): Slavtcheff, Craig Steven
PATENT ASSIGNEE(S): Hindustan Lever Limited, India
SOURCE: Indian, 24 pp.
CODEN: INXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

IN 182391 A1 19990403 IN 1994-BO352 19940803
 PRIORITY APPLN. INFO.: IN 1994-BO352 19940803
 AB A cosmetic composition is described for forming a fast drying peelable face mask. It is based on a combination of polyvinyl alc .(PVA) and a hydrophobically-modified acrylate or methacrylate polymer. Thus, the cosmetic composition contained PVA-523 12 and Ganex V220 2% in addition to the standard cosmetic oil and alc. phase constituents such as glycolic acid, Rosemary, Eucalyptus oil and Tea tree oil.

L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:293355 CAPLUS
 DOCUMENT NUMBER: 129:8415
 ORIGINAL REFERENCE NO.: 129:1813a,1816a
 TITLE: Cleansing products
 INVENTOR(S): Fowler, Timothy John; Hasenoehrl, Erik John; Albacarys, Lourdes Dessus
 PATENT ASSIGNEE(S): Procter & Gamble Co., USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818447	A1	19980507	WO 1997-US19321	19971023
W: AU, CA, CN, CZ, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2269602	A1	19980507	CA 1997-2269602	19971023
AU 9851501	A	19980522	AU 1998-51501	19971023
EP 935456	A1	19990818	EP 1997-946302	19971023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1239882	A	19991229	CN 1997-180467	19971023
JP 2001503059	T	20010306	JP 1998-520635	19971023
KR 2000052801	A	20000825	KR 1999-703620	19990424
AU 749160	B2	20020620	AU 2001-57656	20010726
PRIORITY APPLN. INFO.:			US 1996-740280	A 19961025
			WO 1997-US19321	W 19971023

AB The present invention relates to a substantially dry, disposable, personal cleansing product useful for both cleansing and conditioning the skin or hair. These products are used by the consumer by wetting the dry product with water. The product comprises a water insol. substrate, a lathering surfactant, and a conditioner component. The invention also encompasses methods for cleansing and conditioning the skin or hair using these products and methods for manufacturing these products. A composition was prepared comprising Phase A containing glycerol 10.00, di-Na lauroamphodiacetate (and) Na trideceth sulfate 4.00, Na lauroyl sarcosinate 4.00, Polyquarternium 10 0.25, di-Na EDTA 0.10 weight% and water qs to 100, Phase B containing sucrose ester fatty acid cottonate 3.00, and Phase C containing butylene glycol 2.00 and DMDM Hydantoin (and) isopropynyl carbamate 0.20 weight%.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:293354 CAPLUS
 DOCUMENT NUMBER: 129:8414

ORIGINAL REFERENCE NO.: 129:1813a,1816a
 TITLE: Cleansing products
 INVENTOR(S): Fowler, Timothy John
 PATENT ASSIGNEE(S): Procter & Gamble Co., USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818446	A1	19980507	WO 1997-US19320	19971023
W: AU, CA, CN, CZ, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2269601	A1	19980507	CA 1997-2269601	19971023
AU 9850878	A	19980522	AU 1998-50878	19971023
EP 935455	A1	19990818	EP 1997-913767	19971023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1238684	A	19991215	CN 1997-180187	19971023
JP 2001503058	T	20010306	JP 1998-520634	19971023
KR 2000052804	A	20000825	KR 1999-703623	19990424
PRIORITY APPLN. INFO.:			US 1996-738668	A 19961025
			WO 1997-US19320	W 19971023

AB The present invention relates to a substantially dry, disposable, personal cleansing product useful for both cleansing and conditioning the skin or hair. These products are used by the consumer by wetting the dry product with water. The product comprises a water insol. substrate, a lathering surfactant, and a water soluble conditioning agent. The invention also encompasses methods for cleansing and conditioning the skin or hair using these products and methods for manufacturing these products. A composition was prepared with Phase A containing Na lauroyl sarcosinate 4.00, polyquarternium 10 0.25, di-Na EDTA 0.10, glycerol 10.00, di-Na lauroamphodiacetate (and) Na trideceth sulfate 4.00 weight% and water qs to 100, Phase B contg. sucrose ester fatty acid cottonate 3.00, and Phase C containing butylene glycol 2.00 and DMDM Hydantoin (and) iodopropynyl carbamate 0.20 weight%.

OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1998:293353 CAPLUS
 DOCUMENT NUMBER: 129:8413
 ORIGINAL REFERENCE NO.: 129:1813a,1816a
 TITLE: Cleansing products
 INVENTOR(S): Fowler, Timothy John
 PATENT ASSIGNEE(S): Procter & Gamble Co., USA
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818445	A1	19980507	WO 1997-US19264	19971027
W: AU, CA, CN, CZ, JP, KR, MX				

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 CA 2269296 A1 19980507 CA 1997-2269296 19971027
 AU 9749976 A 19980522 AU 1997-49976 19971027
 EP 938292 A1 19990901 EP 1997-912904 19971027

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 CN 1238685 A 19991215 CN 1997-199960 19971027
 JP 2001503410 T 20010313 JP 1998-520613 19971027
 KR 2000052716 A 20000825 KR 1999-703514 19990422

PRIORITY APPLN. INFO.: US 1996-738145 A 19961025
 WO 1997-US19264 W 19971027

AB The present invention relates to a substantially dry, disposable, personal cleansing product useful for both cleansing and conditioning the skin or hair. These products are used by the consumer by wetting the dry product with water. The product comprises a water insol. substrate, a lathering surfactant, and a water soluble conditioning agent. The invention also encompasses methods for cleansing and conditioning the skin or hair using these products and to methods for manufacturing these products. A composition was prepared comprising Phase A containing glycerol

10.00, di-Na lauroamphodiacetate (and) Na trideceth sulfate 4.00, Na lauroyl sarcosinate 4.00, Polyquarternium 10 0.25, di-Na EDTA 0.10 weight% and water qs to 100, Phase B containing sucrose ester fatty acid cottonate 3.00, and Phase C containing butylene glycol 2.00 and DMDM Hydantoin (and) isopropynyl carbamate 0.20 weight%.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:542894 CAPLUS

DOCUMENT NUMBER: 129:193530

ORIGINAL REFERENCE NO.: 129:39221a,39224a

TITLE: Cosmetics containing carboxyvinyl polymers and α -hydroxy acids

INVENTOR(S): Yokoe, Sonoko; Ikeda, Ako

PATENT ASSIGNEE(S): Sunstar, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10218753	A	19980818	JP 1995-91767	19950324
PRIORITY APPLN. INFO.:			JP 1995-91767	19950324

AB Skin-conditioning prepns. at pH 4-9 comprise 1-2 % carboxyvinyl polymers and 3-12 % α -hydroxy acids, preferably lactic acid. The compns. are stable at the high temperature and cause little irritation to the skin. A peel-off type pack contained carboxyvinyl polymers 1, lactic acid 3.5, 1,3-butylene glycol 5, ethanol 5, polyvinyl alc. 10, parabens 0.2, sorbitan POE monolaurate 0.2, triethanolamine 6.3, and distilled water to 100 %.

L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1987:591024 CAPLUS

DOCUMENT NUMBER: 107:191024

ORIGINAL REFERENCE NO.: 107:30449a,30452a

TITLE: Inhibition of post-surgical adhesion formation by the topical administration of non-steroidal

anti-inflammatory drug
 INVENTOR(S): Sheffield, Warren D.; Johns, Douglas B.; Shalaby, Shalaby W.; Dizerega, Gere S.; Richer, Leroy L.
 PATENT ASSIGNEE(S): Ethicon, Inc., USA
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 225162	A2	19870610	EP 1986-309202	19861126
EP 225162	A3	19871119		
EP 225162	B1	19920122		
R: BE, CH, DE, FR, GB, GR, IT, LI, NL, SE				
IN 166447	A1	19900512	IN 1986-CA787	19861028
CA 1292946	C	19911210	CA 1986-523793	19861125
AU 8665709	A	19870604	AU 1986-65709	19861126
AU 587299	B2	19890810		
JP 62155223	A	19870710	JP 1986-279915	19861126
JP 07098755	B	19951025		
ZA 8608964	A	19880727	ZA 1986-8964	19861126
PRIORITY APPLN. INFO.:			US 1985-802545	A 19851127
			US 1986-900122	A 19860825

AB Postsurgical adhesion formation is inhibited by the topical administration of a non-steroidal antiinflammatory drug, preferably ibuprofen, suprofen, or tolmetin. The drug may be contained in a controlled release vehicle such as absorbable polymer microspheres or phospholipid multilaminar vesicles, or the drug may be administered in conjunction with e.g. Tween 80. Sodium ibuprofen (aq) was added to delyophilized L-alpha-distearoyl phosphatidylcholine and cholesterol. The liposomes formed were .apprx.1 μ m and were stable for several months. Rabbits treated with sodium tolmetin liposomes, which were similarly prepared, developed few adhesions postsurgically. The drug was administered directly to the traumatized site. Tolmetin combined with Tween 80 substantially prevented formation of post-surgical adhesions.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:465419 CAPLUS

DOCUMENT NUMBER: 75:65419

ORIGINAL REFERENCE NO.: 75:10373a,10376a

TITLE: Processed papers. II. Flow properties of coating colors containing poly(vinyl alcohol) derivatives

AUTHOR(S): Kondo, Mitsuru; Dotani, Satoshi; Kamioka, Tadashi

CORPORATE SOURCE: Res. Lab., Kanzaki Pap. Manuf. Co., Ltd., Amagasaki, Japan

SOURCE: Kami Pa Gikyoshi (1971), 25(6), 315-22

CODEN: KAGIAU; ISSN: 0022-815X

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB The flow properties of aqueous clay suspension used in coating papers were studied at the shear rate .apprx.1.5 + 105 sec-1 in a high pressure capillary viscometer. Marked improvements were observed when carboxymethylated poly(vinyl alc.) (I) and phosphated I were used as binders. The coverability (IGT printability tester) of the coating composition was also improved by the binders, and no orange peel pattern or ridges was observed on the coated papers. The coating compns. containing carboxymethylated or phosphated I showed better flow properties than those

containing I or cyanomethylated or acrylamidomethylated I. The flow properties of the coating compns. were also increased with degree of substitution in the modified I and reached optimum values quickly.

=>